Microorganism producing purine nucleotides and method for producing purine nucleotides by using same
By introducing an MFS transporter variant with specific amino acid substitutions in Corynebacterium microorganisms, the production capacity of purine nucleotides like XMP and GMP is enhanced, overcoming the inefficiencies of previous methods.
Patent Information
- Application Number
- PCT/KR2024/006562
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for producing purine nucleotides, such as XMP and GMP, face challenges in increasing production capacity efficiently, despite efforts like target-specific gene expression and gene removal approaches.
Introduction of a Major Facilitator Superfamily (MFS) transporter variant with specific amino acid substitutions in Corynebacterium microorganisms, enhancing their purine nucleotide production ability by optimizing the amino acid sequence at specific positions.
The modified microorganisms exhibit increased purine nucleotide production capacity compared to unmodified counterparts, effectively addressing the limitations of existing production methods.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Microorganism producing purine nucleotides and method for producing purine nucleotides using the same
[0001] The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using the same.
[0002]
[0003] XMP (5'-xanthosine monophosphate) is an intermediate in the nucleic acid biosynthesis metabolic system, and not only has physiological significance in the bodies of plants and animals, but is also widely used in foods, medicines, and various medical purposes. In particular, XMP is one of the nucleic acid seasonings that is attracting attention as a taste-enhancing seasoning because it has a great flavor-enhancing effect when added to food, like monosodium glutamate (MSG), and is a precursor of GMP (5'-guanosine monophosphate).
[0004] To produce XMP, GMP, and other useful substances, various studies are being conducted to develop high-efficiency production microorganisms and fermentation process technologies. For example, target-substance-specific approaches, such as increasing the expression of genes encoding enzymes involved in XMP or GMP biosynthesis or deleting genes unnecessary for biosynthesis, are primarily being utilized (EP 3722430 A1, US 2020-0347346 A1).
[0005] However, as demand for XMP or GMP increases, research is still needed to increase the production capacity of effective XMP or GMP.
[0006]
[0007] The present inventors completed the present application by confirming that the microorganism of the present application can increase its purine nucleotide production ability compared to an existing unmodified microorganism by introducing an MFS transporter mutant.
[0008]
[0009] One aspect of the present application provides an MFS (Major facilitator superfamily) transporter variant, wherein any one amino acid selected from the group consisting of amino acids corresponding to positions 185, 238, 259, 283, 310, 354, 378, 383, and 403 of SEQ ID NO: 1 in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity with SEQ ID NO: 1 is substituted with another amino acid.
[0010] In one specific embodiment, the substitution with said other amino acid may be any one selected from the following:
[0011] (1) The amino acid corresponding to position 259 is replaced with an amino acid selected from among serine (S), threonine (T), phenylalanine (F), proline (P), methionine (M), glutamine (Q), and asparagine (N);
[0012] (2) The amino acid corresponding to position 310 is replaced with an amino acid selected from among alanine (A), phenylalanine (F), cysteine (C), isoleucine (I), glycine (G), methionine (M), tryptophan (W), serine (S), and threonine (T);
[0013] (3) The amino acid corresponding to position 354 is replaced with an amino acid selected from serine (S), tyrosine (Y), asparagine (N), and leucine (L);
[0014] (4) The amino acid corresponding to position 185 is substituted with glutamine (Q);
[0015] (5) The amino acid corresponding to position 238 is replaced with threonine (T);
[0016] (6) The amino acid corresponding to position 283 is substituted with glycine (G);
[0017] (7) The amino acid corresponding to position 378 is replaced with alanine (A);
[0018] (8) The amino acid corresponding to position 383 is substituted with leucine (L); and
[0019] (9) The amino acid corresponding to position 403 is replaced with alanine (A).
[0020] In another specific example, the variant may be one in which an amino acid corresponding to any one position selected from the group consisting of positions 231 and 347 in the amino acid sequence of SEQ ID NO: 3 is substituted with another amino acid.
[0021] In any one of the preceding specific examples, the variant may comprise a substitution selected from among a substitution of the amino acid corresponding to position 231 in the amino acid sequence of SEQ ID NO: 3 with threonine, and a substitution of the amino acid corresponding to position 347 with serine.
[0022] In another specific example, the variant may be one in which the amino acid corresponding to a position selected from the group consisting of positions 216 and 332 in the amino acid sequence of SEQ ID NO: 5 is substituted with another amino acid.
[0023] In any one of the preceding specific examples, the variant may comprise a substitution selected from among a substitution of the amino acid corresponding to position 216 in the amino acid sequence of SEQ ID NO: 5 with threonine, and a substitution of the amino acid corresponding to position 332 with serine.
[0024] Another aspect of the present application provides a polynucleotide encoding the MFS transporter variant.
[0025] Another aspect of the present application provides a vector comprising the polynucleotide.
[0026] Another aspect of the present application provides a microorganism of the genus Corynebacterium, comprising at least one selected from the group consisting of the MFS transporter variant; a polynucleotide encoding the same; and a vector comprising the same.
[0027] In one specific example, the microorganism may have the ability to produce purine nucleotides.
[0028] In any one of the preceding specific examples, the microorganism may have an increased ability to produce purine nucleotides compared to a wild-type Corynebacterium microorganism.
[0029] In any one of the preceding specific examples, the purine nucleotide may be at least one selected from XMP or GMP.
[0030] In another specific example, the microorganism may be Corynebacterium stationis.
[0031] Another aspect of the present application provides a method for producing purine nucleotides, comprising the step of culturing a microorganism of the genus Corynebacterium in a medium, the microorganism comprising at least one selected from the group consisting of the MFS transporter variant; a polynucleotide encoding the same; and a vector comprising the same.
[0032] In one specific example, the method for producing purine nucleotides may further comprise a step of recovering the MFS transporter variant of the present application expressed in the culturing step.
[0033] In another specific embodiment, the purine nucleotide may be at least one selected from XMP or GMP.
[0034] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a microorganism of the genus Corynebacterium, comprising at least one selected from the group consisting of the MFS transporter variant, a polynucleotide encoding the same, and a vector comprising the same; a medium in which the same is cultured; or a combination thereof.
[0035]
[0036] The microorganism of the present application can have increased purine nucleotide production ability compared to an existing unmodified microorganism by introducing an MFS transporter mutant.
[0037]
[0038] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0039] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.
[0040] Additionally, numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety, thereby providing a clearer understanding of the technical field to which this application pertains and the content of this application.
[0041]
[0042] definition
[0043] As used in the specification and appended claims of this application, the singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Unless the context clearly dictates otherwise, the singular terms include the plural and the plural terms include the singular. In the specification and appended claims of this application, unless the context clearly dictates otherwise, the use of "or" is intended to include "and / or."
[0044]
[0045] In this application, the term "consisting essentially of" means that a non-specific component may be present if the characteristics of the subject matter claimed in this application are not substantially affected by the presence of the non-specific component.
[0046] In this application, the term "consisting of" means that the proportion of a specific component(s) totals 100%. The components or features listed below the term "consisting of" may be essential or mandatory. In some embodiments, other than the components or features listed below "consisting of," other optional or nonessential components may be excluded.
[0047] In this application, the term "comprising" means the presence of a feature, step, or component described below, and does not exclude the presence or addition of one or more features, steps, or components. The components or features described below "comprising" in this application may be essential or mandatory, but in some embodiments, other optional or non-essential components or features may be further included.
[0048]
[0049] mutant
[0050] In this application, the term "protein" or "polypeptide" refers to a polymer or oligomer of consecutive amino acid residues. In this application, "polypeptide," "protein," and "peptide" may be used interchangeably with "amino acid sequence."
[0051] In some cases, an amino acid sequence that exhibits activity may be referred to as an "enzyme." In this application, amino acid sequences are described in N-terminal → C-terminal orientation, unless otherwise indicated.
[0052] In this application, the term "mature polypeptide" refers to a polypeptide in a form that lacks a signal sequence or a propeptide sequence. A mature protein / polypeptide / peptide may be a functional form of a protein / polypeptide / peptide. A mature polypeptide may be a final form that has undergone post-translational or post-translational modifications. Examples of post-translational modifications include, but are not limited to, N- or C-terminal modifications, glycosylation, phosphorylation, and leader sequence removal.
[0053]
[0054] In this application, the term "wild type" means a naturally occurring polypeptide without any artificial modifications. When the term "wild type" is used in relation to a polypeptide, it means a naturally occurring polypeptide that does not have any artificial mutations (substitutions, insertions, deletions, etc.) at one or more amino acid positions. Similarly, when the term "wild type" is used in relation to a polynucleotide, it means a polypeptide that does not have any artificial modifications (substitutions, insertions, deletions) at one or more nucleotides. However, a polynucleotide encoding a wild type polypeptide is not limited to a naturally occurring polynucleotide, and also includes a sequence encoding any wild type polypeptide.
[0055] In the present application, the parent sequence or backbone refers to a reference sequence into which a modification is introduced to become a variant. That is, the parent sequence may be a starting sequence and may be a target for introducing mutations such as substitutions, insertions, and / or deletions. The parent sequence may be a naturally occurring or wild type, or a variant in which one or more substitutions, insertions, or deletions have occurred in the natural or wild type, or may be an artificially synthesized sequence. If the parent sequence is an amino acid sequence that exhibits activity, i.e., an amino acid sequence of an enzyme, it may be referred to as a parent enzyme.
[0056] In this application, the term "reference sequence" refers to a sequence used to determine the position of an amino acid within an arbitrary amino acid sequence. By aligning an arbitrary amino acid sequence with a reference sequence, the position of an amino acid corresponding to a specific position of the reference sequence within the arbitrary amino acid sequence can be determined.
[0057]
[0058] In the present application, the term "Nth position" may include the Nth position and an amino acid position corresponding to the Nth position. Specifically, it may include an amino acid position corresponding to any amino acid residue in a mature polypeptide disclosed in a particular amino acid sequence.
[0059]
[0060] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a particular sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.
[0061] In the present application, SEQ ID NO. 1 can be used as a reference sequence to determine the position of an amino acid in any amino acid sequence.
[0062] That is, SEQ ID NO: 1 disclosed in the present application can be used to determine the corresponding amino acid residue in a polypeptide having any MFS transporter activity, and unless otherwise indicated in the present application, residues of a specific amino acid sequence are numbered based on SEQ ID NO: 1.
[0063] For example, any amino acid sequence can be aligned with SEQ ID NO: 1, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 1. For example, a sequence alignment algorithm such as that described in the present application can identify the position of an amino acid, or the position at which a modification such as a substitution, insertion, or deletion occurs, by comparing it to a query sequence (also referred to as a “reference sequence”).
[0064] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000), Trends Genet. 16: 276-277) can be used, but is not limited thereto, and any sequence alignment program known in the art, pairwise sequence comparison algorithm, etc. can be appropriately used.
[0065] Multiple sequence alignment can also be used to identify corresponding amino acid residues in other polypeptides. Examples of multiple sequence alignment programs known in the art include MUSCLE (multiple sequence comparison by log-expectation; version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, Nucleic Acids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research 33: 511-518; Katoh and Toh, 2007, Bioinformatics 23: 372-374; Katoh et al., 2009, Methods in Molecular Biology 537: 39-64; Katoh and Toh, 2010, Bioinformatics 26: 1899-1900), and EMBOSS using ClustalW. EMMA (1.83 or higher; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680), etc., and the default parameters of each of the above programs can be used, but are not limited thereto.
[0066] Additionally, when polypeptides diverge from a mature polypeptide and their relationships cannot be detected by conventional sequence-based comparison, other pairwise sequence comparison algorithms can be used (Lindahl and Elofsson, 2000, J. Mol. Biol. 295: 613-615). Higher sensitivity can be achieved in sequence-based searches by using search programs that utilize probabilistic representations of polypeptide families (profiles) to search databases. For example, the PSI-BLAST program generates profiles through an iterative database search process and can detect remote homologs (Atschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Even greater sensitivity can be achieved when a polypeptide family or superfamily has more than one representation in a protein structure database. Programs such as GenTHREADER (Jones, 1999, J. Mol. Biol. 287: 797-815; McGuffin and Jones, 2003, Bioinformatics 19: 874-881) use information from a variety of sources, such as PSI-BLAST, secondary structure predictions, structural alignment profiles, and solvation potentials, as input to a neural network that predicts the structural folding of a query sequence. Similarly, the method of Gough et al., 2000, J. Mol. Biol. 313: 903-919 can be used to align an unknown sequence with superfamily models available in the SCOP database. These alignments can in turn be used to build homology models for the polypeptide, and these models can be evaluated for accuracy using a variety of tools developed for this purpose.
[0067] For proteins with known structures, several tools and resources are available for searching and generating structural alignments. For example, the SCOP superfamily of proteins is structurally aligned, and these alignments are accessible and downloadable. Two or more protein structures can be aligned using various algorithms, such as distance alignment matrix alignment (Holm and Sander, 1998, Proteins 33: 88-96) or Combinatorial extension (CE) (Shindyalov and Bourne, 1998, Protein Engineering 11: 739-747). Implementations of these algorithms can additionally be used to query structural databases containing the target structure to discover possible structural homologues (Holm and Park, 2000, Bioinformatics 16: 566-567).
[0068] The above methods are examples and are not limiting.
[0069]
[0070] In the present application, with respect to the amino acid sequence, even if it is described as a polypeptide “comprising” the amino acid sequence set forth in a specific sequence number, a polypeptide “consisting of” the amino acid sequence set forth in a specific sequence number, or a polypeptide or protein “having” the amino acid sequence set forth in a specific sequence number, it is obvious that a protein having an amino acid sequence in which a portion of the sequence is deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present application, as long as it has the same or corresponding activity as the protein consisting of the amino acid sequence of the corresponding sequence number. For example, if it has the same or corresponding activity as the above-mentioned mutant protein, it does not exclude sequence additions that do not alter the function of the protein before or after the amino acid sequence, mutations that may occur naturally, silent mutations thereof, or conservative substitutions, and it is obvious that even if it has such sequence additions or mutations, it is also within the scope of the present application.
[0071] For example, if the amino acid sequence has sequence additions, naturally occurring mutations, silent mutations or conservative substitutions that do not alter the function of the variant polypeptide of the present application at the N-terminus, C-terminus and / or within the amino acid sequence.
[0072] In this application, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions may have little or no effect on the activity of the polypeptide.
[0073] In this application, the term "other amino acid" is not limited to an amino acid different from the amino acid prior to substitution. Furthermore, when this application states that "a specific amino acid has been substituted," it is self-evident that the amino acid has been substituted with an amino acid different from the amino acid prior to substitution, even if it is not specifically stated that it has been substituted with another amino acid.
[0074]
[0075] In this application, "mutating / modifying" means changing or altering. This may be a change from a naturally occurring sequence. For example, a polypeptide may be modified in a way that causes the polypeptide to be altered from its parent sequence or reference sequence.
[0076] In the present application, the modified polypeptide may be a polypeptide that does not exist in nature itself, i.e., a non-naturally occurring polypeptide.
[0077] As used herein, the term "modified" means, for example, altered from its naturally occurring form. Modified polypeptides of the present application include non-naturally occurring polypeptides or naturally occurring variants. For example, modified polypeptides of the present application are modified polypeptides not found in nature. For example, modified polypeptides of the present application may be, but are not limited to, those that do not occur spontaneously.
[0078] When the term "modification" is used in relation to an amino acid / nucleic acid sequence in this application, it may include substitution of an amino acid / nucleic acid residue of the parent sequence for a different amino acid / nucleic acid residue at one or more sites in the amino acid sequence, deletion of an amino acid / nucleic acid residue (or a series of amino acid / nucleic acid residues) of the parent sequence at one or more sites, insertion of an amino acid / nucleic acid residue (or a series of amino acid / nucleic acid residues) of the parent sequence at one or more sites, truncation of the N-terminal and / or C-terminal amino acid sequence or 5' and / or 3' nucleic acid sequence, and any combination thereof.
[0079]
[0080] In the present application, the term "variant" or "variant polypeptide" refers to a polypeptide that differs from the parent sequence of the polypeptide by conservative substitution and / or modification of one or more amino acids, but retains the functions or properties of the polypeptide. The variant polypeptide differs from the identified sequence by several amino acid substitutions, deletions, or additions. Such variant polypeptides can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the ability of the variant polypeptide may be increased, unchanged, or decreased compared to the native polypeptide. Additionally, some variant polypeptides may include variant polypeptides in which one or more portions, such as the N-terminal leader sequence or the transmembrane domain, are deleted. Other variant polypeptides may include variants in which portions are deleted from the N- and / or C-terminus of the mature protein. The term "variant polypeptide" may be used interchangeably with terms such as variant, modified, mutated protein, variant, and variant (in English, modification, modified protein, mutant, mutein, divergent, variant, etc.), and is not limited thereto as long as the term is used in the meaning of variant.
[0081] Additionally, the variant polypeptide may contain deletions or additions of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of the polypeptide that is involved in co-translational or post-translational protein transfer. The polypeptide may also be conjugated to other sequences or linkers to facilitate identification, purification, or synthesis of the polypeptide.
[0082]
[0083] The MFS transporter variant of the present application may be in an isolated form.
[0084] As used herein, the term "isolated" refers to a substance that exists in an environment where it does not occur naturally, or in a form that does not occur naturally. This includes the substance (sequence or nucleic acid) being at least substantially free from at least one other component with which it is naturally associated and found in nature, such as a sequence or nucleic acid.
[0085] For example, the isolated sequences or nucleic acids provided in the present application may be provided in a form substantially free of one or more contaminants.
[0086] Examples of isolated substances may include, but are not limited to, i) any non-naturally occurring substance, ii) any substance from which one, more, or all naturally occurring components associated with it in nature have been removed (e.g., an enzyme, variant, nucleic acid, protein, peptide, or cofactor), iii) any substance found in nature that has been artificially modified, or iv) a substance that has been modified to alter the amount of that substance relative to other naturally associated components (e.g., increasing the number of copies of a gene encoding the substance; modifying a promoter naturally associated with a gene encoding the substance to a more active promoter, etc.).
[0087] In the present application, with respect to amino acid or nucleic acid sequences, the term "biologically active fragments" or "fragments" may refer to "functional fragments." A "functional fragment," also referred to as an active fragment, refers to a polypeptide that contains fewer amino acids than a full-length protein but retains at least one biological activity of the corresponding full-length protein. For example, a functional fragment of an enzyme may comprise the catalytic site of the enzyme.
[0088] The MFS transporter variant of the present application may comprise biologically active fragments of the MFS transporter variant. The biologically active fragments may comprise a portion of the full length of the native polypeptide.
[0089] For example, it may contain, but is not limited to, at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or less than 100% of the amino acids of the full length of the native polypeptide.
[0090]
[0091] Throughout this application, the conventional one-letter and three-letter codes for naturally occurring amino acids are used. Furthermore, amino acids referred to by abbreviations in this application are described according to the IUPAC-IUB nomenclature.
[0092]
[0093] Alanine Ala, A Arginine Arg, R
[0094] Asparagine Asn, N Aspartic acid Asp, D
[0095] Cysteine Cys, C Glutamic acid Glu, E
[0096] Glutamine Gln, Q Glycine Gly, G
[0097] Histidine His, H Isoleucine Ile, I
[0098] Leucine Leu, L Lysine Lys, K
[0099] Methionine Met, M Phenylalanine Phe, F
[0100] Proline Pro, P Serine Ser, S
[0101] Threonine Thr, T Tryptophan Trp, W
[0102] Tyrosine Tyr, Y Valine Val, V
[0103]
[0104] Meanwhile, any amino acid can be written as Xaa, X.
[0105] Additionally, the generally accepted three-letter codes for other amino acids, such as Aib (2-Aminoisobutyric acid), Sar (N-methylglycine), and α-methyl-glutamic acid, may be used, as well as for naturally occurring amino acids.
[0106]
[0107] Amino acids can generally be classified based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of their residues.
[0108] As examples of this classification, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; amino acids with nonpolar side chains (nonpolar amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline; and amino acids with polar or hydrophilic side chains (polar amino acids) include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, amino acids with charged side chains (electrically charged amino acids) include arginine, lysine, histidine, glutamic acid, and aspartic acid; and amino acids with uncharged side chains (also called neutral amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, phenylalanine, tryptophan, and tyrosine can be classified as aromatic amino acids. As another example, valine, leucine, and isoleucine can be classified as branched amino acids. As another example, the 20 amino acids can be classified by size into five groups: glycine, alanine, and serine; cysteine, proline, threonine, aspartic acid, and asparagine; valine, histidine, glutamic acid, and glutamine; isoleucine, leucine, methionine, lysine, and arginine; and phenylalanine, tryptophan, and tyrosine. However, this is not necessarily limited to these groups.
[0109]
[0110] To describe the variants provided in this application, the following nomenclature is used.
[0111] In this application, reference to a specific position in an amino acid sequence may include reference to an amino acid present or substituted at that position. Reference to an amino acid at a specific position may be described in various ways. For example, "position 003" may be described as "position 3," "amino acid 3," or "the third amino acid." Furthermore, for example, if the amino acid at position 3 is serine (S), it may be described as "S3" or "Ser3."
[0112] Amino acid substitutions can be expressed by listing the amino acid before substitution, the position, and the amino acid being replaced. These amino acids can be expressed using conventional one-letter and three-letter codes. For example, if alanine, the amino acid at position 8 in a specific sequence, is replaced with valine, it can be written as "A8V" or "Ala8Val."
[0113] Any amino acid at a particular position can be designated as "X". For example, X6 refers to any amino acid at position 6. Also, when a substituted amino acid is designated as X, it means that it is replaced with an amino acid different from the amino acid present before the substitution. For example, "V6X" indicates that V is replaced with any amino acid other than V at position 6.
[0114]
[0115] polynucleotide
[0116] As used herein, the term "gene" refers to a polynucleotide encoding a polypeptide and a polynucleotide comprising regions preceding and following the coding region. In some embodiments, a gene may have a sequence (intron) inserted between each coding region (exon).
[0117]
[0118] In this application, the term "polynucleotide, nucleic acid or nucleic acid molecule" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, and a strand of DNA (e.g., cDNA or genomic DNA) or RNA (e.g., mRNA) of a certain length or longer.
[0119]
[0120] homology, identity
[0121] As used herein, the terms "homology" or "identity" refer to the degree of relationship between two given amino acid sequences or nucleic acid sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.
[0122] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences are generally capable of hybridizing under moderate or high stringency conditions, typically along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its entire length. It should be appreciated that hybridization also encompasses polynucleotides containing common codons or codons that are considered codon degenerate.
[0123] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO et al.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information Database.
[0124] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using, for example, the GAP computer program disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2:482, or, for example, Needleman et al. (1970), J Mol Biol. 48:443. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). The default parameters for the GAP program are (1) unitary matrices (containing values of 1 for identity and 0 for non-identity), the PAM Matrix (see the disclosure by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation (1978)), Gribskov et al (1986) Nucl. Acids Res. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0125] Additionally, whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York), but are not limited thereto.
[0126] In this application, the term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8). For example, conditions under which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions under which washing conditions of typical southern hybridization are performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1×SSC, 0.1% SDS, specifically 60°C, 0.1×SSC, 0.1% SDS, and more specifically 68°C, 0.1×SSC, 0.1% SDS.
[0127] The above hybridization requires that the two nucleotides have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Accordingly, the polynucleotide of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.
[0128] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0129]
[0130] Nucleic acid structures, vectors, and transformation
[0131] The term "nucleic acid construct" in this application means a single or double-stranded nucleic acid molecule that contains one or more regulatory sequences and is artificially synthesized, engineered to contain a specific sequence in a manner that does not exist in nature, or isolated from nature.
[0132]
[0133] The term "vector" as used herein refers to a DNA construct comprising a nucleic acid sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or may be integrated into the genome itself.
[0134] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pDC series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. For example, pCR, pDCM2, pDZ, pDC, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. can be used.
[0135] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0136] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism, thereby enabling expression of the polypeptide encoded by the polynucleotide in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or located extrachromosomally, as long as it can be expressed in the host cell. Furthermore, the polynucleotide includes DNA and RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. Additionally, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0137] As used herein, the term "operably linked" refers to a configuration in which a regulatory sequence is positioned appropriately to direct the expression of a coding sequence. Therefore, "operably linked" includes a regulatory region of a functional domain with known or desired activity, such as a promoter, terminator, signal sequence, or enhancer region, attached or linked to a target (gene or polypeptide) so as to regulate the expression, secretion, or function of the target in accordance with said known or desired activity. For example, it refers to a polynucleotide sequence that is operatively linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target variant polypeptide of the present application.
[0138] As used herein, the term “expression” includes, but is not limited to, any step involved in the production of a polypeptide, such as transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0139] As used herein, the term "expression vector" means a linear or circular nucleic acid molecule comprising a coding sequence and regulatory sequences operably linked thereto for expression thereof.
[0140] As used herein, the term "regulatory sequence" refers to a polynucleotide sequence necessary for the expression of a coding sequence. Each regulatory sequence may be native to the coding sequence (having the same origin) or foreign (derived from another gene). Examples of the regulatory sequence include a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, a signal peptide sequence, an operator sequence, a sequence encoding a ribosome binding site, and sequences that regulate transcription and translation termination. The minimum unit of the regulatory sequence may include a promoter, a transcription and translation termination sequence.
[0141]
[0142] In relation to a cell, polynucleotide, polypeptide, or vector, the term "recombinant" in this application means that the cell, polynucleotide, polypeptide, or vector has been modified by the introduction of a heterologous nucleic acid or polypeptide or by alteration of a native polynucleotide or polypeptide, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell may express a gene not found in the native (non-recombinant) form of the cell, or may express a native gene that is expressed or not expressed at all, or otherwise abnormally expressed.
[0143]
[0144] microorganism
[0145] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification, either naturally or artificially. It may be a microorganism that has a specific mechanism weakened or increased due to causes such as the insertion of an external gene or the increased or inactivated activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein, or product. In this application, "microorganism" and "strain" may be used interchangeably without limitation with the same meaning.
[0146] For example, the microorganism of the present application may be a microorganism comprising an MFS transporter variant or a polynucleotide encoding the same; or a microorganism genetically modified to include an MFS transporter variant or a polynucleotide encoding the same (e.g., a recombinant strain).
[0147]
[0148] The strain of the present application may be a strain that naturally possesses purine nucleotide production ability, or a microorganism in which purine nucleotide production ability has been conferred on a strain that lacks purine nucleotide production ability. For example, the strain may be a microorganism in which purine nucleotide production ability has been increased by introducing the MFS transporter variant of the present application or a polynucleotide encoding the same, but is not limited thereto.
[0149] The strain of the present application may be a microorganism having increased purine nucleotide production ability compared to a parent strain or a wild-type Corynebacterium strain that does not include the variant of the present application. The microorganism may have improved purine nucleotide production ability by introducing the MFS transporter variant of the present application having increased MFS transporter activity compared to a wild-type MFS transporter or a polynucleotide encoding the same. Specifically, the strain of the present application may have increased purine nucleotide production ability compared to a Corynebacterium microorganism that includes an amino acid sequence having 75% or more sequence identity with SEQ ID NO: 1, more specifically, a wild-type MFS transporter having any one of SEQ ID NOs: 1, 3, or 5, or a polynucleotide encoding the same.
[0150]
[0151] In the present application, the term "microorganism having purine nucleotide production ability" refers to a prokaryotic or eukaryotic microbial strain capable of producing purine nucleotides within the organism, and may include both a microorganism in which the purine nucleotide production ability has been conferred on a parent strain lacking purine nucleotide production ability, and a microorganism that inherently has purine nucleotide production ability. The purine nucleotide production ability may be conferred or enhanced by species improvement.
[0152]
[0153] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation due to natural or artificial factors. The "unmodified microorganism" may be used interchangeably with "pre-modified strain," "pre-modified microorganism," "unmutated strain," "unmodified strain," "unmutated microorganism," "pre-mutated parent strain," "wild-type microorganism," "reference microorganism," or "reference microorganism." In addition, the term "MFS transporter unmodified microorganism" in this application may refer to a strain into which the MFS transporter variant described herein is not introduced or before it is introduced. The MFS transporter unmodified microorganism in this application does not exclude a strain that contains a modification of a protein or another gene other than a modification of the MFS transporter or a polynucleotide encoding the same. In addition, in the present application, the non-modified microorganism may be a microorganism comprising an amino acid sequence having a sequence identity of 75% or more with SEQ ID NO: 1, specifically, an amino acid sequence of any one of SEQ ID NOs: 1, 3, or 5, or a polynucleotide of any one of SEQ ID NOs: 2, 4, or 6, but is not limited thereto.
[0154]
[0155] Increased polypeptide activity
[0156] As used herein, the term "increase" of polypeptide activity means an increase in the activity of the polypeptide relative to its intrinsic activity. This increase may be used interchangeably with terms such as activation, up-regulation, overexpression, and enhancement.
[0157] The increase may include exhibiting an activity that was not originally present, or exhibiting an activity that is enhanced compared to the intrinsic activity or activity prior to modification.
[0158] For example, the above "exhibiting an activity that was not originally present" may be, but is not limited to, "introduction of a protein." The introduction of a protein refers to the expression of a gene that the microorganism did not originally possess, thereby exhibiting the activity of a specific protein, or the expression of an increased or improved activity compared to the intrinsic activity or activity before modification of the protein. For example, a polynucleotide encoding a specific protein may be introduced into the chromosome of a microorganism, or a vector containing a polynucleotide encoding a specific protein may be introduced into the microorganism, thereby exhibiting its activity.
[0159] The above “intrinsic activity” refers to the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification.”
[0160] An increase in the activity of a polypeptide compared to its intrinsic activity means that the activity and / or concentration (expression amount) of a specific polypeptide is improved compared to the activity and / or concentration (expression amount) that the parent strain or unmodified microorganism originally had before the transformation.
[0161] By way of example only, the increase may be, but is not limited to, an increase in the activity or concentration of the corresponding protein, typically by about 1%, about 10%, about 25%, about 50%, about 75%, about 100%, about 150%, about 200%, about 300%, about 400%, or about 500%, up to about 1000% or about 2000% or more, relative to the activity or concentration of the wild-type protein or the initial microbial strain.
[0162] An increase in the activity of the polypeptide can be achieved by introducing an exogenous polypeptide or by increasing the activity of the endogenous polypeptide. Whether the activity of the polypeptide has increased can be confirmed by an increase in the activity level of the polypeptide, the amount of expression, or the amount of a product excreted from the polypeptide.
[0163] The increase in the activity of the polypeptide can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be increased compared to the microorganism before transformation. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but are not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
[0164] Specifically, the increase in activity of the polypeptide of the present application is
[0165] 1) Increase in the intracellular copy number of a polynucleotide encoding a polypeptide;
[0166] 2) Modification of the gene expression control region on the chromosome encoding the polypeptide (e.g., mutation in the expression control region, replacement with a sequence having stronger activity, or insertion of a sequence having stronger activity);
[0167] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;
[0168] 4) Modification of the amino acid sequence of the polypeptide so as to increase polypeptide activity;
[0169] 5) Modification of a polynucleotide sequence encoding said polypeptide such that the polypeptide activity is increased (e.g., modification of a polynucleotide sequence of said polypeptide gene such that the polypeptide activity is increased such that the polypeptide activity is increased);
[0170] 6) Introduction of a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same;
[0171] 7) Codon optimization of a polynucleotide encoding a polypeptide;
[0172] 8) Analyzing the tertiary structure of the polypeptide and selecting the exposed portion to modify or chemically modify; or
[0173] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0174] for example,
[0175] The increase in the intracellular copy number of the polynucleotide encoding the polypeptide described above may be caused by the introduction of a vector into the host cell, to which the polynucleotide encoding the polypeptide is operably linked and which can replicate and function independently of the host. Alternatively, the polynucleotide encoding the polypeptide may be introduced into the chromosome of the host cell in one copy or two or more copies. The introduction into the chromosome may be performed by the introduction into the host cell of a vector capable of inserting the polynucleotide into the chromosome of the host cell, but is not limited thereto. The vector is as described above.
[0176] 2) Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence having strong activity may be, for example, a mutation in the sequence such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further increase the activity of the expression control region, or replacement with a sequence having stronger activity. The expression control region may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. As an example, it may be, but is not limited to, replacing the original promoter with a strong promoter.
[0177] Examples of known strong promoters include, but are not limited to, the cj1 to cj7 promoters (US Patent No. US 7662943 B2), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the rhtB promoter, the SPL7 promoter, the SPL13 (sm3) promoter (US Patent No. US 10584338 B2), the O2 promoter (US Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.
[0178] 3) The above modification of the base sequence of the initiation codon or 5'-UTR region of the gene encoding the polypeptide may be, for example, a substitution of another initiation codon having a higher polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0179] The modification of the amino acid sequence or polynucleotide sequence of the above 4) and 5) may be, but is not limited to, a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution or a combination thereof in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to increase the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to have increased activity. The replacement may be specifically performed by inserting the polynucleotide into a chromosome by homologous recombination, but is not limited thereto. The vector used at this time may additionally include a selection marker to confirm whether or not the chromosome has been inserted. The selection marker is as described above.
[0180] The introduction of the foreign polynucleotide exhibiting the activity of the polypeptide as described above 6) may be the introduction into the host cell of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide. The foreign polynucleotide is not limited in its origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction may be performed by a person skilled in the art by appropriately selecting a known transformation method, and the polypeptide may be produced by expressing the introduced polynucleotide in the host cell, thereby increasing its activity.
[0181] The above 7) codon optimization of a polynucleotide encoding a polypeptide may be codon optimization of an endogenous polynucleotide to increase transcription or translation within a host cell, or codon optimization of a foreign polynucleotide to achieve optimized transcription or translation within a host cell.
[0182] The above 8) analyzing the tertiary structure of a polypeptide and selecting an exposed portion to modify or chemically modify may be done by, for example, comparing the sequence information of the polypeptide to be analyzed with a database storing the sequence information of known proteins, determining a template protein candidate based on the degree of sequence similarity, confirming the structure based on this, and selecting an exposed portion to modify or chemically modify, and modifying or modifying it.
[0183] Such an increase in polypeptide activity may be, but is not limited to, an increase in the activity or concentration of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild-type or pre-transformed microbial strain, or an increase in the amount of a product produced from the polypeptide.
[0184]
[0185] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0186]
[0187] culture
[0188] In this application, the term "cultivation" refers to growing the strain of this application under appropriately controlled environmental conditions. The cultivation process of this application can be performed using any suitable medium and culture conditions known in the art. This cultivation process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the cultivation may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0189] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the strain of this application may be any medium used for culturing general microorganisms without particular limitation. However, the microorganism of this application may be cultured under aerobic conditions in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin, while controlling temperature, pH, etc. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0190] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0191] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0192] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0193] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0194] In the culture of the present application, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.
[0195] In the present application, the term "culture" means a culture solution, concentrated culture solution, dried product of culture solution, culture filtrate, concentrated culture filtrate, or dried product of culture filtrate obtained by culturing a specific microorganism in a culture medium, wherein the culture solution means that it contains a specific microorganism, and the culture filtrate means that it does not substantially contain a specific microorganism (here, substantially means that a specific microorganism separated by filtration or the like is excluded, but does not mean that the filtrate is completely free of microorganisms). The culture is not limited in its formulation, and may be, for example, a liquid, an emulsion, or a solid.
[0196] In this application, the term "fermentation" refers to a process in which microorganisms use their enzymes to decompose organic matter, but not to a putrefaction reaction. While fermentation and putrefaction occur through similar processes, if the resulting decomposition produces useful substances, it is called fermentation. If the resulting decomposition produces foul-smelling or harmful substances, it is called putrefaction.
[0197] In the present application, the method for obtaining a fermented product from the strain is not particularly limited, and can be obtained according to a method commonly used in the relevant technical field or a similar field.
[0198] In the present application, the term "fermentation" includes all kinds of materials including a fermentation product produced from the strain, such as not only the fermented material itself, but also a culture medium of the strain in which the strain and the culture coexist, a fermentation product obtained by filtering the strain from the culture medium, a fermentation product obtained by sterilizing the strain from the culture medium and filtering it, an extract obtained by extracting the fermentation product or a culture medium containing it, a diluted solution obtained by diluting the fermentation product or its extract, a concentrate obtained by drying the fermentation product or its extract, a lysate obtained by capturing and crushing the cells of the strain, etc.
[0199]
[0200] Specific description of this application
[0201] Hereinafter, specific examples of the present application will be described in more detail as follows.
[0202]
[0203] One aspect of the present application provides an MFS transporter variant.
[0204] The term "MFS transporter" in the present application refers to a membrane transport protein belonging to the Major facilitator superfamily (MFS), which facilitates the movement of small solutes across the cell membrane in response to a chemiosmotic gradient. The MFS transporter may be a protein having the activity of excreting XMP. The "MFS transporter" may be used interchangeably with "MFS transporter", "MFS transporter", "xmpE", or "xmpE protein".
[0205] The amino acid sequence of the above MFS transporter can be obtained from a known database such as NCBI's Genbank.
[0206] The MFS transporter of the present application may be derived from a microorganism of the genus Corynebacterium.
[0207] For example, the wild type of the MFS transporter provided in the present application may be an MFS transporter derived from Corynebacterium stationis, Corynebacterium genus J010B-136, Corynebacterium ammoniagenes, Corynebacterium casei, Corynebacterium glutamicum, Corynebacterium crudilactis or Corynebacterium callunae. Examples include NCBI Accession numbers WP_088859234.1, HJG64956.1, WP_156489138.1, NME89867.1, HHT58321.1, WP_156845106.1, WP_105323823.1, AMJ45871.1, OAH32741.1, WP_205906775.1, WP_040355997.1, NMF31380.1, AQS74831.1, WP_205908328.1, HCJ69685.1, WP_006822858.1, WP_004568051.1, WP_011897033.1, WP_087061877.1, WP_077311687.1, WP_060564322.1, HJE11205.1, WP_065366770.1, WP_059289024.1, WP_038583410.1, WP_074491550.1, WP_011014092.1, WP_172768437.1, WP_087497622.1, WP_006285236.1, WP_096455209.1, WP_208400728.1, WP_208396345.1, NWO08766.1, Sequences such as WP_066565157.1, WP_003856921.1, WP_247776084.1, or WP_015650879.1 can be cited.
[0208] As another example, the wild-type MFS transporter may be a polypeptide comprising, consisting of, or consisting essentially of an amino acid sequence having a sequence identity of at least 60%, preferably at least 75%, with SEQ ID NO: 1, specifically an amino acid sequence as set forth in any one of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, but is not limited thereto.
[0209] In the present application, the parent sequence of the MFS transporter, i.e. the MFS transporter to be mutated, may include, without limitation, not only the wild-type MFS transporter described above, but also a sequence having the same activity as the amino acid sequence of the wild-type MFS transporter.
[0210] Specifically, the parent sequence of the MFS transporter may include an amino acid sequence represented by any one of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, or an amino acid sequence having at least 60%, for example, at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with any one of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5. In addition, it is obvious that a protein having an amino acid sequence in which a part of the sequence is deleted, modified, substituted, or added is also included within the scope of the present application, as long as it has such homology or identity and exhibits an effect corresponding to the protein.
[0211] Meanwhile, in the present application, the expression "an amino acid corresponding to a specific position in a specific amino acid sequence is substituted" is interpreted to mean that the amino acid sequence is used as a reference sequence, and in this case, the parent sequence may have any structure unless otherwise defined. Examples of the parent sequence are as described above.
[0212]
[0213] The MFS transporter variant provided in the present application is a variant having MFS transporter activity, which comprises a substitution of an amino acid selected from the group consisting of amino acids corresponding to positions 185, 238, 259, 283, 310, 354, 378, 383 and 403 from the N-terminus of SEQ ID NO: 1 in any polypeptide having MFS transporter activity or in an MFS transporter, with another amino acid.
[0214] The MFS transporter variant of the present application may have enhanced MFS transporter activity compared to the polypeptide before mutation, the natural wild-type polypeptide, the unmodified polypeptide, or the polypeptide of the parent sequence.
[0215] In addition, through sequence alignment, the positions corresponding to the 238th and 354th positions from the N-terminus of the sequence number 1 may be the 231st and 347th positions, respectively, based on the sequence number 3, and may be the 216th and 332nd positions, respectively, based on the sequence number 5.
[0216] Accordingly, one embodiment of the MFS transporter variant provided in the present application may be an MFS transporter variant in which an amino acid corresponding to a position selected from the group consisting of positions 231 and 347 in the amino acid sequence of SEQ ID NO: 3 is substituted with another amino acid, and / or an MFS transporter variant in which an amino acid corresponding to a position selected from the group consisting of positions 216 and 332 in the amino acid sequence of SEQ ID NO: 5 is substituted with another amino acid.
[0217] Additionally, the description of the 238th amino acid of SEQ ID NO: 1 in this application can be applied to the 231st amino acid of SEQ ID NO: 3 and the 216th amino acid of SEQ ID NO: 5, and the description of the 354th amino acid of SEQ ID NO: 1 can be applied to the 347th amino acid of SEQ ID NO: 3 and the 332nd amino acid of SEQ ID NO: 5.
[0218]
[0219] For example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 185 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0220] For example, the MFS transporter variant of the present application may have leucine (L), an amino acid corresponding to position 185 in the amino acid sequence of SEQ ID NO: 1, substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0221] For example, the MFS transporter variant of the present application may be one in which leucine, an amino acid corresponding to position 185 in the amino acid sequence of SEQ ID NO: 1, is substituted with glutamine.
[0222] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 185 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be glutamine.
[0223] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 7.
[0224]
[0225] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 238 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0226] For example, the MFS transporter variant of the present application may be one in which isoleucine (I), an amino acid corresponding to position 238 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0227] For example, the MFS transporter variant of the present application may have isoleucine, an amino acid corresponding to position 238 in the amino acid sequence of SEQ ID NO: 1, substituted with threonine.
[0228] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 238 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be threonine.
[0229] It is self-evident that the MFS transporter variant of the present application may include deletions or additions of amino acids that have minimal impact on the characteristics and secondary structure of the MFS transporter, such as substitution of the amino acid at position 238 of SEQ ID NO: 1 with another amino acid, as described above. Furthermore, those skilled in the art would know through sequence alignment known in the art that position 238 from the N-terminus of SEQ ID NO: 1 of the present application corresponds to position 231 of SEQ ID NO: 3 and position 216 of SEQ ID NO: 5.
[0230] Accordingly, as an example of the MFS transporter variant of the present application, a variant in which the amino acid corresponding to position 238 of SEQ ID NO: 1 (the 231st amino acid in SEQ ID NO: 3, the 216th amino acid in SEQ ID NO: 5) is substituted for SEQ ID NO: 3 and SEQ ID NO: 5 can be cited.
[0231] Additionally, the description of the 238th amino acid of SEQ ID NO: 1 in this application can be applied to the 231st amino acid of SEQ ID NO: 3 and the 216th amino acid of SEQ ID NO: 5.
[0232] For example, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 238th amino acid of SEQ ID NO: 1 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 1. In another embodiment, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 231st amino acid of SEQ ID NO: 3 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 3. In another embodiment, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 216th amino acid of SEQ ID NO: 5 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 5.
[0233] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of any one of the amino acid sequences of SEQ ID NOs: 131, 133, and 137.
[0234]
[0235] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 259 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0236] For example, the MFS transporter variant of the present application may have isoleucine (I), an amino acid corresponding to position 259 in the amino acid sequence of SEQ ID NO: 1, substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0237] For example, the MFS transporter variant of the present application may be one in which isoleucine, an amino acid corresponding to position 259 in the amino acid sequence of SEQ ID NO: 1, is substituted with an amino acid selected from serine, threonine, phenylalanine, proline, methionine, glutamine, and asparagine.
[0238] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 259 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be an amino acid selected from serine, threonine, phenylalanine, proline, methionine, glutamine, and asparagine.
[0239] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of an amino acid sequence of any one of SEQ ID NOs: 55, 57, 59, 75, 81, 85, and 91.
[0240]
[0241] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 283 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0242] For example, the MFS transporter variant of the present application may have serine (S), an amino acid corresponding to position 283 in the amino acid sequence of SEQ ID NO: 1, substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, or valine.
[0243] For example, the MFS transporter variant of the present application may have serine, an amino acid corresponding to position 283 in the amino acid sequence of SEQ ID NO: 1, substituted with glycine.
[0244] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 283 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be glycine.
[0245] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 15.
[0246]
[0247] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 310 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0248] For example, the MFS transporter variant of the present application may be one in which valine (V), an amino acid corresponding to position 310 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, or tyrosine.
[0249] For example, the MFS transporter variant of the present application may be one in which valine, an amino acid corresponding to position 310 in the amino acid sequence of SEQ ID NO: 1, is substituted with an amino acid selected from alanine, phenylalanine, cysteine, isoleucine, glycine, methionine, tryptophan, serine, and threonine.
[0250] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 310 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be an amino acid selected from alanine, phenylalanine, cysteine, isoleucine, glycine, methionine, tryptophan, serine, and threonine.
[0251] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of an amino acid sequence of any one of SEQ ID NOs: 93, 95, 97, 105, 111, 117, 119, 121, and 123.
[0252]
[0253] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 354 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0254] For example, the MFS transporter variant of the present application may be one in which phenylalanine (F), an amino acid corresponding to position 354 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0255] For example, the MFS transporter variant of the present application may be one in which valine, an amino acid corresponding to position 354 in the amino acid sequence of SEQ ID NO: 1, is substituted with an amino acid selected from serine, tyrosine, asparagine, and leucine.
[0256] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 354 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be an amino acid selected from serine, tyrosine, asparagine, and leucine.
[0257] It is self-evident that the MFS transporter variant of the present application may include deletions or additions of amino acids that have minimal impact on the characteristics and secondary structure of the MFS transporter, such as substitution of the amino acid at position 354 of SEQ ID NO: 1 with another amino acid, as described above. Furthermore, those skilled in the art would know through sequence alignment known in the art that position 354 from the N-terminus of SEQ ID NO: 1 of the present application corresponds to position 347 of SEQ ID NO: 3 and position 332 of SEQ ID NO: 5.
[0258] Accordingly, as an example of the MFS transporter variant of the present application, a variant in which the amino acid corresponding to position 354 of SEQ ID NO: 1 (the 347th amino acid in SEQ ID NO: 3, the 332nd amino acid in SEQ ID NO: 5) corresponding to position 354 of SEQ ID NO: 1 is substituted for SEQ ID NO: 3 and SEQ ID NO: 5 can be cited.
[0259] Additionally, the description of the 354th amino acid of SEQ ID NO: 1 in this application can be applied to the 347th amino acid of SEQ ID NO: 3 and the 332nd amino acid of SEQ ID NO: 5.
[0260] For example, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 354th amino acid of SEQ ID NO: 1 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 1. In another embodiment, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 347th amino acid of SEQ ID NO: 3 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 3. In another embodiment, the MFS transporter variant of the present application may include an amino acid sequence in which the amino acid at the position corresponding to the 332nd amino acid of SEQ ID NO: 5 is substituted with a different amino acid, and may have at least 75% but less than 100% sequence homology with SEQ ID NO: 5.
[0261] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of any one of the amino acid sequences of SEQ ID NOs: 17, 19, 21, 51, 135, and 139.
[0262]
[0263] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 378 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0264] For example, the MFS transporter variant of the present application may be one in which valine (V), an amino acid corresponding to position 378 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, or tyrosine.
[0265] For example, the MFS transporter variant of the present application may be one in which valine, an amino acid corresponding to position 378 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine.
[0266] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 378 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be alanine.
[0267] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 9.
[0268]
[0269] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 383 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0270] For example, the MFS transporter variant of the present application may be one in which isoleucine (I), an amino acid corresponding to position 383 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0271] For example, the MFS transporter variant of the present application may have isoleucine, an amino acid corresponding to position 383 in the amino acid sequence of SEQ ID NO: 1, substituted with leucine.
[0272] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 383 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be leucine.
[0273] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 11.
[0274]
[0275] As another example, the MFS transporter variant provided in the present application may mean a variant in which, among the proteins having the MFS transporter activity described above, the amino acid corresponding to position 403 of sequence number 1 is replaced with a different amino acid compared to the parent sequence, and thus the activity exceeds 100% compared to the protein of the parent sequence.
[0276] For example, the MFS transporter variant of the present application may be one in which valine (V), an amino acid corresponding to position 403 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, or tyrosine.
[0277] For example, the MFS transporter variant of the present application may be one in which valine, an amino acid corresponding to position 403 in the amino acid sequence of SEQ ID NO: 1, is substituted with alanine.
[0278] For example, the variant may include an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1, wherein the amino acid at a position corresponding to amino acid position 403 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. For example, the other amino acid may be alanine.
[0279] The above variant may be, but is not limited to, a variant comprising, consisting of, or consisting essentially of the amino acid sequence of SEQ ID NO: 13.
[0280]
[0281] In one embodiment among the above-described embodiments, the MFS transporter variant provided in the present application is a variant having MFS transporter activity, in which an amino acid corresponding to a position selected from the group consisting of the 231st and 347th positions from the N-terminus of SEQ ID NO: 3 in any polypeptide or MFS transporter having MFS transporter activity is substituted with another amino acid. For example, the variant may include a substitution selected from the group consisting of a substitution of the amino acid corresponding to the 231st position in the amino acid sequence of SEQ ID NO: 3 with threonine, and a substitution of the amino acid corresponding to the 347th position with serine.
[0282]
[0283] In another embodiment among the above-described embodiments, the MFS transporter variant provided in the present application is a variant having MFS transporter activity, in which an amino acid corresponding to a position selected from the group consisting of the 216th and 332nd positions from the N-terminus of SEQ ID NO: 5 in any polypeptide having MFS transporter activity or an MFS transporter is substituted with another amino acid. For example, the variant may include a substitution selected from the group consisting of a substitution of the amino acid corresponding to the 216th position in the amino acid sequence of SEQ ID NO: 5 with threonine, and a substitution of the amino acid corresponding to the 332nd position with serine.
[0284] The variants of the present application are those having sequence numbers 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, A variant comprising, consisting of, or consisting essentially of an amino acid sequence represented by any one of the sequence numbers selected from among 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, and 139; or a polypeptide having at least 60%, for example at least 75%, homology or sequence identity thereto, but is not limited thereto.
[0285]
[0286] Another aspect of the present application provides a polynucleotide encoding an MFS transporter variant of the present application.
[0287] The polynucleotide encoding the MFS transporter variant of the present application may include, without limitation, any polynucleotide sequence encoding the MFS transporter variant having enhanced activity of the present application.
[0288] The polynucleotide of the present application may have various modifications in the coding region within a range that does not change the amino acid sequence of the polypeptide due to codon degeneracy or in consideration of the codons preferred in the organism to which the polypeptide is to be expressed. Specifically, the polynucleotide may include, without limitation, a polynucleotide sequence encoding a variant in which an amino acid selected from the group consisting of amino acids corresponding to positions 185, 238, 259, 283, 310, 354, 378, 383, and 403 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid.
[0289] For example, the polynucleotide of the present application is a variant of the present application, specifically, the polynucleotide of the above SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, A polypeptide comprising, consisting of, or consisting essentially of an amino acid sequence represented by any one of the sequence numbers selected from among 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, and 139; or a polynucleotide sequence encoding a polypeptide having at least 60%, for example at least 75%, sequence homology or identity thereto, but is not limited thereto.
[0290] In addition, as described above, the MFS transporter variant of the present application includes a variant in which the amino acid corresponding to the 238th position from the N-terminus of SEQ ID NO: 1 (the 231st amino acid in SEQ ID NO: 3, the 216th amino acid in SEQ ID NO: 5) is substituted for SEQ ID NO: 3 and SEQ ID NO: 5, or a variant in which the amino acid corresponding to the 354th position from the N-terminus of SEQ ID NO: 1 (the 347th amino acid in SEQ ID NO: 3, the 332nd amino acid in SEQ ID NO: 5) is substituted, and therefore, the polynucleotide sequence encoding the MFS transporter variant is also included in the scope of the present application.
[0291] In addition, a probe that can be prepared from a known genetic sequence, for example, a probe that can hybridize under stringent conditions with a complementary sequence to all or part of the base sequence, and a sequence encoding a protein having the activity of a variant in which an amino acid selected from the group consisting of amino acids corresponding to positions 185, 238, 259, 283, 310, 354, 378, 383, and 403 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid, may be included without limitation.
[0292]
[0293] Another aspect of the present application provides a vector comprising a polynucleotide encoding an MFS transporter variant of the present application.
[0294]
[0295] Another aspect of the present application provides a microorganism comprising one or more of the MFS transporter variant, a polynucleotide encoding the same, and a vector comprising the same.
[0296] The microorganism comprising at least one of the above MFS transporter variant, a polynucleotide encoding the variant, and a vector comprising the same may be a microorganism produced by transformation with a vector comprising a polynucleotide encoding the variant, but is not limited thereto.
[0297] The above microorganism may be a microorganism expressing an MFS transporter variant.
[0298] In this application, the term "protein to be / is / is expressed" may refer to a state in which the target protein is introduced into a microorganism or modified to be expressed within the microorganism. For the purposes of this application, the "target protein" may be the aforementioned MFS transporter variant.
[0299] Specifically, "introduction of a protein" may mean that a microorganism exhibits activity of a specific protein that it did not originally possess, or exhibits activity that is enhanced compared to the protein's inherent activity or activity prior to modification. For example, a polynucleotide encoding a specific protein may be introduced into the chromosome of a microorganism, or a vector containing a polynucleotide encoding a specific protein may be introduced into the microorganism, resulting in its activity.
[0300]
[0301] The above microorganism may be a recombinant microorganism, and the recombination may be achieved by genetic modification such as transformation.
[0302]
[0303] As an example of the present application, the microorganism of the present application may have enhanced MFS transporter activity.
[0304] The above "enhanced activity" may refer to enhanced activity of a specific protein of a microorganism compared to its inherent activity or activity prior to modification. "Intrinsic activity" may refer to the activity of a specific protein originally possessed by the parent strain prior to a change in phenotype, when the phenotype of a microorganism changes due to genetic mutation caused by natural or artificial factors.
[0305] Specifically, in the present application, the enhancement of the activity of the protein variant may be achieved by one or more of, but is not limited to, increasing the intracellular copy number of the gene encoding the protein variant, introducing a mutation into the expression control sequence of the gene encoding the protein variant, replacing the expression control sequence of the gene encoding the protein variant with a sequence having strong activity, replacing a gene encoding a native protein having MFS transporter activity on a chromosome with a gene encoding the protein variant, and additionally introducing a mutation into the gene encoding the variant so as to enhance the activity of the protein variant.
[0306] Next, modifying the expression control sequence to increase the expression of the polynucleotide may be performed by, but is not particularly limited to, inducing a sequence mutation in the nucleic acid sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control sequence, or by replacing the nucleic acid sequence with a nucleic acid sequence having stronger activity. The expression control sequence may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, a sequence regulating the termination of transcription and translation, etc.
[0307] A strong promoter may be linked upstream of the above polynucleotide expression unit instead of the original promoter, but is not limited thereto. Examples of known strong promoters include, but are not limited to, cj1 to cj7 promoters (Korean Patent No. 10-0620092), lac promoter, trp promoter, trc promoter, tac promoter, lambda phage PR promoter, PL promoter, tet promoter, gapA promoter, SPL7 promoter, SPL13 (sm3) promoter (Korean Patent No. 10-1783170), O2 promoter (Korean Patent No. 10-1632642), tkt promoter, and yccA promoter.
[0308] In addition, modification of a polynucleotide sequence on a chromosome may be performed, but is not particularly limited thereto, by inducing mutations in the expression regulatory sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof of the nucleic acid sequence to further enhance the activity of the polynucleotide sequence, or by replacing it with a polynucleotide sequence that has been improved to have stronger activity.
[0309] Such introduction and enhancement of protein activity may be, but is not limited to, an increase in the activity or concentration of the corresponding protein, typically by at least 1%, 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, or up to 1000% or 2000%, relative to the activity or concentration of the protein in a wild-type or unmodified microbial strain.
[0310]
[0311] As another example of the present application, the microorganism of the present application may be a microorganism having the ability to produce purine nucleotides.
[0312] The microorganism of the present application may be a microorganism with improved purine nucleotide production ability.
[0313] In the present application, the term "purine nucleotide" may be at least one selected from XMP (5'-xanthosine monophosphate, 5'-xanthic acid), GMP (5'-guanosine monophosphate, 5'-guanidine acid), and IMP (5'-inosine monophosphate, 5'-inosinic acid). Specifically, the purine nucleotide of the present application may be XMP or GMP. XMP refers to a nucleotide dehydrogenated from IMP. The XMP can be synthesized from IMP by 5'-inosine-5'-monophosphate dehydrogenase, but is not limited thereto. GMP has a structure in which a phosphate group forms an ester bond to the ribose portion in a guanosine molecule, and can be synthesized by adding an ammonia molecule to XMP by 5'-guanidine biosynthetic enzyme (GMP synthase), but is not limited thereto.
[0314]
[0315] The microorganism of the present application may be a microorganism that naturally has purine nucleotide production ability or a microorganism in which purine nucleotide production ability is increased or granted by introducing an MFS transporter variant or a polynucleotide encoding the same into a parent strain that does not have purine nucleotide production ability, but is not limited thereto.
[0316] For the purpose of the present application, the recombinant microorganism of the present application may be a Corynebacterium strain having increased purine nucleotide production ability compared to a natural wild-type Corynebacterium strain or a Corynebacterium strain producing purine nucleotides, including a protein having endogenous MFS transporter activity or a polynucleotide encoding the same, by introducing the MFS transporter variant or the polynucleotide encoding the same into the natural wild-type microorganism or the Corynebacterium strain producing purine nucleotides, but is not limited thereto. For example, the above-described wild-type Corynebacterium strain or the Corynebacterium strain that produces purine nucleotides, including a protein having endogenous MFS transporter activity or a polynucleotide encoding the same, may be a target strain for comparing whether the purine nucleotide production ability or MFS transporter activity increases as described above, but is not limited thereto.
[0317] For example, the recombinant strain with increased purine nucleotide production ability has an increase in purine nucleotide production ability of about 0.5% or more, specifically, about 1% or more, about 2% or more, about 3% or more, about 4% or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more, about 12% or more, about 13% or more, about 14% or more, about 15% or more, about 16% or more, about 17% or more, about 18% or more, about 19% or more, about 20% or more, about 21% or more, or about 22% or more (the upper limit is not particularly limited, and for example, about 200% or less, about 150% or less, about 100% or less, about 50% or less, about 40% or more) compared to the purine nucleotide production ability of the parent strain or the unmodified microorganism before mutation. The increase may be less than, or equal to, about 30% or less, about 20% or less, or about 15% or less), but is not limited thereto, as long as it has a positive increase compared to the productivity of the parent strain or unmodified microorganism before the mutation. In another example, the microorganism with increased purine nucleotide production ability has a purine nucleotide production ability of about 1.005 times or more, about 1.01 times or more, about 1.02 times or more, about 1.03 times or more, about 1.04 times or more, about 1.05 times or more, about 1.06 times or more, about 1.07 times or more, about 1.08 times or more, about 1.09 times or more, about 1.1 times or more, about 1.11 times or more, about 1.12 times or more, about 1.13 times or more, about 1.14 times or more, about 1.15 times or more, about 1.16 times or more, about 1.17 times or more, about 1.18 times or more, about 1.19 times or more, about 1.2 times or more, about 1.21 times or more, or about It may be increased by 1.22 times or more (the upper limit is not particularly limited, for example, it may be about 10 times or less, about 5 times or less, about 3 times or less, or about 2 times or less), but is not limited thereto.
[0318] This productivity can be evaluated by measuring the production amount of the target product obtained by culturing in a medium. The evaluation can be performed by measuring the production amount of the target product using a suitable method known in the art. For example, HPLC (High Performance Liquid Chromatography), GC (Gas Chromatography), GC / MS (Gas Chromatography-Mass Spectrometry), LC / MS (Liquid chromatography-mass spectrometry), GPC (Gel Permeation Chromatography) or a combination of these methods can be used, and the production amount of the target product can be measured using a suitable method known in the art.
[0319]
[0320] The microorganism of the present application may be any microorganism that expresses an MFS transporter variant, including the polynucleotide of the present application or the vector of the present application.
[0321] Specifically, Corynebacterium stationis, Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium pollutisoli pollutisoli), Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens, and specifically Corynebacterium stationenis or Corynebacterium ammoniagenes. However, the term "microorganism" is not limited thereto and includes microorganisms that are taxonomically homologous thereto regardless of the name of the microorganism.
[0322]
[0323] As another example of the present application, the microorganism of the present application may be a microorganism with enhanced purine nucleotide production ability by further enhancing the activity of some proteins in the purine nucleotide biosynthesis pathway or by further weakening the activity of some proteins in the purine nucleotide degradation pathway.
[0324] In one embodiment among the above-described embodiments, the recombinant microorganism of the present application may be a microorganism (Korean Patent No. 10-1929158) in which the activity of xmpE is enhanced by increasing the copy number of xmpE; replacing the promoter of xmpE with a promoter with enhanced activity; replacing the start codon of xmpE; or a combination thereof, in order to enhance the purine nucleotide biosynthesis pathway.
[0325] In another embodiment of the aforementioned embodiments, the recombinant microorganism of the present application may be a microorganism with enhanced activity of a phosphate uptake system (Pit system) (Korean Patent Publication No. 10-2022-0157782). However, the present invention is not limited thereto.
[0326]
[0327] In this application, the term "attenuation" of the activity of a polypeptide encompasses both a decrease in activity or the absence of activity compared to the intrinsic activity. The term "attenuation" may be used interchangeably with terms such as inactivation, deficiency, down-regulation, decrease, reduce, and attenuation.
[0328] The above weakening may also include cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall polypeptide activity level and / or concentration (expression amount) within the cell is lower than that of the natural strain due to inhibition of expression of the gene of the polynucleotide encoding the polypeptide or inhibition of translation into a polypeptide, cases where the polynucleotide is not expressed at all, and / or cases where the polypeptide has no activity even if the polynucleotide is expressed. The above "intrinsic activity" refers to the activity of a specific polypeptide originally possessed by the parent strain, wild type, or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before modification." The term "weakening, inactivation, deficiency, reduction, downregulation, deterioration, attenuation" of the activity of a polypeptide relative to its intrinsic activity means that the activity of a particular polypeptide is lowered compared to the activity that the parent strain or unmodified microorganism originally had prior to the transformation.
[0329] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
[0330]
[0331] Specifically, the weakening of the activity of the polypeptide of the present application is
[0332] 1) Deletion of all or part of a gene encoding a polypeptide;
[0333] 2) Modification of the expression control region (or expression control sequence) so as to reduce the expression of the gene encoding the polypeptide;
[0334] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;
[0335] 4) Modification of the gene sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotide bases in the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);
[0336] 5) Modification of the base sequence encoding the initiation codon, Shine-Dalgarno sequence or 5'-UTR region of a gene transcript encoding a polypeptide;
[0337] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;
[0338] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence to the front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible;
[0339] 8) Addition of a promoter that is transcribed in the opposite direction to the 3' end of the open reading frame (ORF) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE); or
[0340] 9) Control of cellular localization of proteins (polypeptides); or
[0341] 10) It may be a combination of two or more selected from 1) to 9), but is not particularly limited thereto.
[0342] for example,
[0343] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having some nucleotides deleted, or replacement with a marker gene.
[0344] The above 2) modification of the expression control region (or expression control sequence) may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0345] The modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of the gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.
[0346] The above 5) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0347] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
[0348] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible may render mRNA translation impossible or slow it down.
[0349] In addition, the addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.
[0350] The above 9) regulation of the intracellular location of a protein (polypeptide) may target the protein (polypeptide) to a specific organelle or specific intracellular space within the cell. For example, targeting to the periplasm or cytoplasm may be achieved by adding or removing a leader sequence that functions in targeting the protein (polypeptide), but is not limited thereto.
[0351] Such attenuation of polypeptide activity may include, but is not limited to, a decrease in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or a decrease in the amount of a product produced from the polypeptide.
[0352]
[0353] Another aspect of the present application provides a method for producing purine nucleotides, comprising the step of culturing a microorganism of the genus Corynebacterium in a medium, the microorganism comprising at least one selected from the group consisting of the MFS transporter variant; a polynucleotide encoding the same; and a vector comprising the same.
[0354] The method for producing purine nucleotides of the present application may include a step of culturing in a medium a microorganism in which an MFS transporter variant or a gene encoding the same is enhanced; or a microorganism genetically modified to further enhance an MFS transporter variant or a gene encoding the same, wherein the microorganism is as described above.
[0355] The above MFS transporter variant may have increased MFS transporter activity compared to a wild-type MFS transporter derived from a Corynebacterium genus microorganism. Alternatively, the MFS transporter variant may not be endogenously expressed in a Corynebacterium genus microorganism.
[0356]
[0357] Purine nucleotides produced by the culture of the present invention may be secreted into the medium or remain within the cells.
[0358] The purine nucleotide may be XMP or GMP, as described above.
[0359]
[0360] The method for producing purine nucleotides of the present application may additionally include a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the microorganism, or a combination thereof (in any order), for example, before the culturing step.
[0361] The purine nucleotide production method of the present application may further include a step of recovering purine nucleotides from the culture medium (medium in which culture is performed) or the cultured microorganism. The recovering step may be additionally included after the culturing step.
[0362] The above recovery may be performed by collecting the desired purine nucleotide using a suitable method known in the art according to the culture method of the microorganism of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the desired purine nucleotide may be recovered from the medium or microorganism using a suitable method known in the art.
[0363] Additionally, the purine nucleotide production method of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the purine nucleotide production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0364] In the method of the present application, the MFS transporter variant, polynucleotide, vector, purine nucleotide, strain, etc. are as described in the other aspects above.
[0365]
[0366] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a microorganism of the genus Corynebacterium, comprising at least one selected from the group consisting of the MFS transporter variant, a polynucleotide encoding the same, and a vector comprising the same; a medium in which the same is cultured; or a combination thereof.
[0367]
[0368] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing purine nucleotides, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonic agents.
[0369]
[0370] Another aspect of the present application provides a method for producing a Corynebacterium strain producing purine nucleotides, comprising the step of introducing at least one selected from the MFS transporter variant, a polynucleotide encoding the same, and a vector comprising the same into the Corynebacterium strain.
[0371] The above MFS transporter variants, polynucleotides, vectors, purine nucleotides and strains are as described above.
[0372]
[0373] The above manufacturing method may include a step of modifying a microorganism such that the microorganism has increased MFS transporter activity compared to its intrinsic activity. This includes introducing an MFS transporter mutant into a strain of the genus Corynebacterium.
[0374]
[0375] Another aspect of the present application provides a use of a strain of the genus Corynebacterium, wherein at least one selected from the group consisting of the MFS transporter variant, a polynucleotide encoding the same, and a vector comprising the same is introduced, for producing purine nucleotides.
[0376]
[0377] The above MFS transporter variants, polynucleotides, vectors, purine nucleotides, strains, etc. are as described in the other aspects above.
[0378]
[0379] Hereinafter, this application will be described in more detail through examples and experimental examples. However, these examples and experimental examples are intended to exemplify this application and the scope of this application is not limited to these examples and experimental examples.
[0380]
[0381] Example 1: Production of a random mutant library of MFS (Major facilitator superfamily) transporters and confirmation of XMP (5'-xanthosine monophosphate) production ability of strains introducing MFS transporter mutations.
[0382]
[0383] 1-1. Creating a random mutation library vector
[0384] A random mutant library vector was constructed to introduce mutations into the endogenous MFS transporter of Corynebacterium stationis (WP_088859234.1, SEQ ID NO: 1).
[0385] Specifically, using an error-prone PCR kit (clontech Diversify® PCR Random Mutagenesis Kit), a library of randomly mutagenized MFS transporter mutants was amplified using the genomic DNA of Corynebacterium stationensis ATCC6872 as a template and the primer pairs of SEQ ID NO: 141 and SEQ ID NO: 142. The amplified product was cloned into the pCR vector using a TOPO cloning kit (Invitrogen), transformed into Escherichia coli DH5α, and plated on LB solid medium containing 25 mg / L kanamycin. The transformed colonies were collected to extract the plasmid, which was named pCR-xmpE random library.
[0386] The primer sequences used here are as shown in Table 1 below.
[0387]
[0388] Sequence number Sequence name Sequence (5'-> 3') 141xmpE CFAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGTTATCATGGGGTGGGTCGCC 142xmpE CRTGAATTGTAATACGACTCACTATAGGGCGAATTGGGCCCTTTATTGAGCCAGAACCATGG
[0389]
[0390] 1-2. Selection of strains introducing MFS transporter mutations and confirmation of XMP production ability
[0391] The pCR-xmpE random library produced in Example 1-1 was transformed into Corynebacterium ammoniagenes strain KCCM10530 (Korean Patent No. 10-0542568) producing XMP by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545) and plated on a nutrient medium containing 25 mg / L of kanamycin. From this, 5,000 colonies in which mutations were introduced into the MFS transporter were obtained, and each colony was named KCCM10530_pCR-xmpE(mt)1 to KCCM10530_pCR-xmpE(mt)5000.
[0392] The composition of the above nutrient medium is as follows.
[0393]
[0394] <XMP 영양배지>
[0395] Glucose 1%, Peptone 1%, Meat Juice 1%, Sodium Chloride 0.25%, Yeast Extract 1%, Adenine 100mg / L, Guanine 100mg / L, Agar 2%, pH 7.2 (based on 1 liter of distilled water)
[0396]
[0397] The 15,000 colonies obtained were each autoclaved and inoculated into a 96-deep well plate containing 100 ㎕ of a seed medium containing 25 mg / L kanamycin, and cultured with shaking at 1200 rpm for 24 hours at 30℃ in a microplate shaker (TAITEC) to use as a seed culture. 320 ㎕ of the autoclaved production medium below (240 ㎕ of main medium + 80 ㎕ of a separate sterilized medium) was dispensed into a 96-deep well plate, and 15 ㎕ of the seed culture was inoculated into each plate, and cultured with shaking for 72 hours under the same conditions as above.
[0398] The compositions of the above seed medium, main medium, and separate sterilized medium are as follows.
[0399]
[0400] <XMP 플라스크 종배지>
[0401] Glucose 30g / L, Peptone 15g / L, Yeast Extract 15g / L, Sodium Chloride 2.5g / L, Urea 3g / L, Adenine 150mg / L, Guanine 150mg / L, pH 7.0 (based on 1 liter of distilled water)
[0402]
[0403] <XMP Flask Production Medium (Main Medium)>
[0404] Glucose 50g / L, Magnesium sulfate 10g / L, Yeast extract 3g / L, Calcium chloride 100mg / L, Iron sulfate 20mg / L, Manganese sulfate 10mg / L, Zinc sulfate 10mg / L, Copper sulfate 0.8mg / L, Histidine 20mg / L, Cystine 15mg / L, Beta-Alanine 15mg / L, Biotin 100ug / L, Thiamine 5mg / L, Adenine 50mg / L, Guanine 25mg / L, Niacin 15mg / L, pH 7.0 (based on 1 liter of distilled water)
[0405]
[0406] <XMP flask production medium (separate sterilized medium)>
[0407] 18g / L of monopotassium phosphate, 42g / L of dipotassium phosphate, 7g / L of urea, 5g / L of ammonium sulfate (based on 1 liter of distilled water)
[0408]
[0409] To analyze the production of XMP in the culture medium, 640 μL of sterile water was dispensed into the culture medium after completion of the culture, centrifuged at 4000 rpm for 15 minutes, and 3 μL of the supernatant was transferred to a 96-well UV plate dispensed with 297 μL of distilled water. After stirring for 30 seconds using a microplate reader, the absorbance was measured with a spectrophotometer at 25℃ and 260nm wavelength. The mutant strains with similar or decreased absorbance compared to the control strain (KCCM10530) were excluded, and 12 mutant strains with increased absorbance compared to the control strain (KCCM10530_pCR-xmpE(mt)_559, KCCM10530_pCR-xmpE(mt)_618, KCCM10530_pCR-xmpE(mt)_1218, KCCM10530_pCR-xmpE(mt)_1512, KCCM10530_pCR-xmpE(mt)_2372, KCCM10530_pCR-xmpE(mt)_2826, KCCM10530_pCR-xmpE(mt)_3194, KCCM10530_pCR-xmpE(mt)_3451, KCCM10530_pCR-xmpE(mt)_4028, KCCM10530_pCR-xmpE(mt)_4317, KCCM10530_pCR-xmpE(mt)_4737, KCCM10530_pCR-xmpE(mt)_4888) were selected.
[0410]
[0411] 1-3. Confirmation of XMP production ability of selected MFS transporter mutant introduced strains
[0412] To verify the effectiveness of XMP production from the selected strains, fermentation activity was evaluated. KCCM10530 as a control strain and 12 mutant strains selected above were inoculated into 14 mL tubes containing 2.5 mL of seed medium, respectively, and cultured with shaking at 170 rpm at 30°C for 24 hours. 0.7 mL of the seed culture was inoculated into a 250 mL corner-baffle flask containing 32 mL of production medium (24 mL of main medium + 8 mL of a separate sterilized medium), and cultured with shaking at 170 rpm at 30°C for 75 hours. After completion of the culture, the production amount of XMP was measured using HPLC, and the results are shown in Table 2 below.
[0413]
[0414] Strain nameMutantXMP concentration(g / L)Control groupKCCM10530WT10.91KCCM10530_pCR-xmpE(mt)_559F354S11.92KCCM10530_pCR-xmpE(mt)_618L185Q11.43KCCM10530_pCR-xmpE(mt)_1218V378A11.74KCCM10530_pCR-xmpE(mt)_1512I383L11.65KCCM10530_pCR-xmpE(mt)_2372F354Y12.26KCCM10530_pCR-xmpE(mt)_282 6I238T12.07KCCM10530_pCR-xmpE(mt)_3194I259T14.18KCCM10530_pCR-xmpE(mt)_3451F354N13.29KCCM10530_pCR-xmpE(mt)_4028V403A 11.610KCCM10530_pCR-xmpE(mt)_4317S283G11.311KCCM10530_pCR-xmpE(mt)_4737I259S11.412KCCM10530_pCR-xmpE(mt)_4888V310A11.5
[0415]
[0416] As shown in Table 2 above, 12 mutant strains with mutations introduced into the MFS transporter and increased absorbance were confirmed to have increased XMP production compared to the control strain KCCM10530.
[0417] To confirm the mutant sequence introduced onto the MFS transporter in the 12 mutant strains with increased XMP production ability mentioned above, PCR and base sequence analysis were performed on each strain using the primer pair of SEQ ID NO: 143 and SEQ ID NO: 144.
[0418] The primer sequences used here are as shown in Table 3 below.
[0419]
[0420] Sequence number Sequence name Sequence (5'-> 3') 143xmpE seq FGGAATCCGCTGTCATGATCT 144xmpE seq RTCGCAGTTCACGCACTAAAG
[0421]
[0422] As a result of comparing the polynucleotide sequences of gene fragments encoding MFS transporter mutations derived from 12 secured mutant strains with the gene sequence encoding MFS transporter derived from the control strain KCCM10530, KCCM10530_pCR-xmpE(mt)_559 had a mutation in which the 354th amino acid from the N-terminus of the MFS transporter was substituted from phenylalanine (F) to serine (S), KCCM10530_pCR-xmpE(mt)_618 had a mutation in which the 185th amino acid from the N-terminus of the MFS transporter was substituted from leucine (L) to glutamine (Q), and KCCM10530_pCR-xmpE(mt)_1218 had a mutation in which the 378th amino acid from the N-terminus of the MFS transporter was substituted from valine (V) to alanine (A). KCCM10530_pCR-xmpE(mt)_1512 is a mutation in which the 383rd amino acid from the N-terminus of the MFS transporter is substituted from isoleucine(I) to leucine(L), KCCM10530_pCR-xmpE(mt)_2372 is a mutation in which the 354th amino acid from the N-terminus of the MFS transporter is substituted from phenylalanine(F) to tyrosine(Y), KCCM10530_pCR-xmpE(mt)_2826 is a mutation in which the 238th amino acid from the N-terminus of the MFS transporter is substituted from isoleucine(I) to threonine(T), and KCCM10530_pCR-xmpE(mt)_3194 is a mutation in which the 259th amino acid from the N-terminus of the MFS transporter is substituted from isoleucine(I). A mutation in which threonine (T) is substituted, KCCM10530_pCR-xmpE(mt)_3451 is a mutation in which the 354th amino acid from the N-terminus of the MFS transporter is substituted from phenylalanine (F) to asparagine (N), KCCM10530_pCR-xmpE(mt)_4028 is a mutation in which the 403rd amino acid from the N-terminus of the MFS transporter is substituted from valine (V) to alanine (A), and KCCM10530_pCR-xmpE(mt)_4317 is a mutation in which the 283rd amino acid from the N-terminus of the MFS transporter is substituted from serine (S) to glycine (G).It was confirmed that KCCM10530_pCR-xmpE(mt)_4737 contains a mutation in which the 259th amino acid from the N-terminus of the MFS transporter is substituted from isoleucine (I) to serine (S), and KCCM10530_pCR-xmpE(mt)_4888 contains a mutation in which the 310th amino acid from the N-terminus of the MFS transporter is substituted from valine (V) to alanine (A).
[0423]
[0424] Example 2: Vector for introducing MFS transporter mutations and confirmation of XMP production ability of Corynebacterium stationaris introducing MFS transporter mutations
[0425]
[0426] 2-1. Vector creation for introducing MFS transporter mutations
[0427] In order to introduce the MFS transporter mutations identified in the 12 strains with increased XMP production ability in the above Examples 1-2 into the endogenous MFS transporter of Corynebacterium stationensis, a vector for introducing the 12 MFS transporter mutations was constructed.
[0428] Specifically, KCCM10530_pCR-xmpE(mt)_559, KCCM10530_pCR-xmpE(mt)_618, KCCM10530_pCR-xmpE(mt)_1218, KCCM10530_pCR-xmpE(mt)_1512, KCCM10530_pCR-xmpE(mt)_2372, KCCM10530_pCR-xmpE(mt)_2826, KCCM10530_pCR-xmpE(mt)_3194, KCCM10530_pCR-xmpE(mt)_3451, KCCM10530_pCR-xmpE(mt)_4028, PCR was performed using the chromosomes of KCCM10530_pCR-xmpE(mt)_4317, KCCM10530_pCR-xmpE(mt)_4737, and KCCM10530_pCR-xmpE(mt)_4888 as templates and the primer pairs of SEQ ID NO: 143 and SEQ ID NO: 144.
[0429] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, polymerization at 72°C for 60 seconds, and then polymerization at 72°C for 5 minutes, repeated 30 times.
[0430] Recombinant vectors were obtained by cloning each PCR product amplified above and vector pDCM2 (Korean Publication No. 10-2020-0136813) for insertion and replacement of genes in the Corynebacterium chromosome digested with XbaI restriction enzyme using Gibson assembly (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix). Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar number and storing it at 50°C for 1 hour. The 12 recombinant vectors constructed above were named pDCM2-xmpE(F354S), pDCM2-xmpE(L185Q), pDCM2-xmpE(V378A), pDCM2-xmpE(I383L), pDCM2-xmpE(F354Y), pDCM2-xmpE(I238T), pDCM2-xmpE(I259T), pDCM2-xmpE(F354N), pDCM2-xmpE(V403A), pDCM2-xmpE(S283G), pDCM2-xmpE(I259S), and pDCM2-xmpE(V310A) vectors, respectively.
[0431]
[0432] 2-2. Production of Corynebacterium stationaris with MFS transporter mutations
[0433] Each of the 12 recombinant vectors produced in Example 2-1 was transformed into Corynebacterium stationis KCCM12248P strain (Korean Patent No. 10-1929158) producing XMP by electroporation, thereby obtaining strains in which each vector was inserted into the chromosome by recombination of homologous sequences. The strains were selected on a medium containing 25 mg / L of kanamycin. The selected primary strain was subjected to a second crossover, and a strain in which a mutation was introduced into the gene encoding the MFS transporter was selected. The genetic manipulation was confirmed through PCR and base sequence analysis using the primer pair of SEQ ID NO: 143 and SEQ ID NO: 144.
[0434] The 12 strains obtained above were KCCM12248P::xmpE(F354S), KCCM12248P::xmpE(L185Q), KCCM12248P::xmpE(V378A), KCCM12248P::xmpE(I383L), KCCM12248P::xmpE(F354Y), KCCM12248P::xmpE(I238T), KCCM12248P::xmpE(I259T), KCCM12248P::xmpE(F354N), KCCM12248P::xmpE(V403A), KCCM12248P::xmpE(S283G), KCCM12248P::xmpE(I259S), It was named KCCM12248P::xmpE(V310A).
[0435]
[0436] 2-3. Confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutation
[0437] KCCM12248P::xmpE(F354S), KCCM12248P::xmpE(L185Q), KCCM12248P::xmpE(V378A), KCCM12248P::xmpE(I383L), KCCM12248P::xmpE(F354Y), KCCM12248P::xmpE(I238T), KCCM12248P::xmpE(I259T), KCCM12248P::xmpE(F354N), KCCM12248P::xmpE(V403A), KCCM12248P::xmpE(S283G), KCCM12248P::xmpE(I259S), manufactured in the above Example 2-2 The XMP production ability of 12 strains of KCCM12248P::xmpE(V310A) and KCCM10530, KCCM12248P was confirmed through the fermentation activity evaluation method of Example 1-3. After completion of cultivation, the production amount of XMP was measured using HPLC, and the cultivation results are as shown in Table 4 below.
[0438]
[0439] Strain name XMP concentration (g / L) XMP yield (%) Control group KCCM10530 10.92 1.8 Control group KCCM12248P 13.5 27.01 KCCM12248P::xmpE(F354S) 15.93 1.82 KCCM12248P::xmpE(L185Q) 14.3 28.63 KCCM12248P::xmpE(V378A) 14.7 29.44 KCCM12248P::xmpE(I383L) 14.5 29.05 KCCM12248P::xmpE(F354Y) 15.6 3 1.26 KCCM12248P ::xmpE(I238T)15.330.67KCCM12248P::xmpE(I259T)14.629.28KCCM12248P::xmpE(F354N)16.533.09KCCM12248P::xmpE(V403A )14.228.410KCCM12248P::xmpE(S283G)15.430.811KCCM12248P::xmpE(I259S)14.929.812KCCM12248P::xmpE(V310A)14.529.0
[0440]
[0441] As shown in Table 4 above, the Corynebacterium stationieris strain into which the MFS transporter mutation was introduced showed a significant increase in XMP production compared to the control strain KCCM10530, and in particular, it was confirmed that the XMP production increased by 5% to 22% or more compared to the parent strain KCCM12248P.
[0442]
[0443] Example 3: Vector for introducing mutations at position F354 of the MFS transporter and confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutations
[0444]
[0445] 3-1. Vector creation for introducing MFS transporter mutations
[0446] In the above Example 2-3, it was confirmed that XMP production ability could be increased when the 354th amino acid from the N-terminus of the MFS transporter was mutated. Therefore, site-directed mutagenesis was performed using the pDCM2-xmpE (F354S) vector produced in the above Example 2-1 as a template to produce a vector in which the 354th amino acid was replaced with another amino acid.
[0447] Specifically, a primer pair of SEQ ID NO: 145 and SEQ ID NO: 146 for introducing the F354C mutation into the gene encoding the MFS transporter, a primer pair of SEQ ID NO: 147 and SEQ ID NO: 148 for introducing the F354R mutation, a primer pair of SEQ ID NO: 149 and SEQ ID NO: 150 for introducing the F354I mutation, a primer pair of SEQ ID NO: 151 and SEQ ID NO: 152 for introducing the F354V mutation, a primer pair of SEQ ID NO: 153 and SEQ ID NO: 154 for introducing the F354D mutation, a primer pair of SEQ ID NO: 155 and SEQ ID NO: 156 for introducing the F354G mutation, a primer pair of SEQ ID NO: 157 and SEQ ID NO: 158 for introducing the F354P mutation, a primer pair of SEQ ID NO: 159 and SEQ ID NO: 160 for introducing the F354A mutation, and a primer pair of SEQ ID NO: 161 for introducing the F354E mutation. And site-directed PCR was performed using the primer pair of SEQ ID NO: 162 for introducing the F354M mutation, the primer pair of SEQ ID NO: 163 and SEQ ID NO: 164 for introducing the F354W mutation, the primer pair of SEQ ID NO: 165 and SEQ ID NO: 166 for introducing the F354W mutation, the primer pair of SEQ ID NO: 167 and SEQ ID NO: 168 for introducing the F354T mutation, the primer pair of SEQ ID NO: 169 and SEQ ID NO: 170 for introducing the F354Q mutation, the primer pair of SEQ ID NO: 171 and SEQ ID NO: 172 for introducing the F354K mutation, the primer pair of SEQ ID NO: 173 and SEQ ID NO: 174 for introducing the F354L mutation, and the primer pair of SEQ ID NO: 175 and SEQ ID NO: 176 for introducing the F354H mutation.
[0448] The primer sequences used here are as shown in Table 5 below.
[0449]
[0450]
[0451]
[0452] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, followed by 24 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 10 minutes, followed by polymerization at 72°C for 5 minutes. The PCR product amplified above was treated with DpnI restriction enzyme to remove pDCM2-xmpE (F354S) used as a template, and then transformed into E. coli DH5a to obtain a vector in which the 354th amino acid of the MFS transporter was modified with the desired amino acid. The 16 vectors obtained above were pDCM2-xmpE(F354C), pDCM2-xmpE(F354R), pDCM2-xmpE(F354I), pDCM2-xmpE(F35V), pDCM2-xmpE(F354D), pDCM2-xmpE(F354G), respectively. pDCM2-xmpE(F354P), pDCM2-xmpE(F354A), pDCM2-xmpE(F354E), pDCM2-xmpE(F354M), pDCM2-xmpE(F354W), pDCM2-xmpE(F354T), pDCM2-xmpE(F354Q), pDCM2-xmpE(F354K), pDCM2-xmpE(F354L), It was named pDCM2-xmpE(F354H).
[0453]
[0454] 3-2. Production of Corynebacterium stationaris with MFS transporter mutations
[0455] Each of the 16 vectors manufactured in Example 3-1 was transformed into the Corynebacterium stationarynis KCCM12248P strain by electroporation, thereby obtaining strains in which each vector was inserted into the chromosome by recombination of homologous sequences. The strains were selected on a medium containing 25 mg / L of kanamycin. The selected primary strains were subjected to a second round of crossing, and a strain in which the 354th amino acid of the MFS transporter was modified to the desired amino acid was selected. The genetic manipulation was confirmed through PCR using the primer pairs of SEQ ID NOs: 141 and 142 and base sequence analysis using the primer pairs of SEQ ID NOs: 143 and 144.
[0456] The 16 strains obtained above were respectively named as KCCM12248P::xmpE(F354C), KCCM12248P::xmpE(F354R), KCCM12248P::xmpE(F354I), KCCM12248P::xmpE(F354V), KCCM12248P::xmpE(F354D), KCCM12248P::xmpE(F354G), KCCM12248P::xmpE(F354P), KCCM12248P::xmpE(F354A), KCCM12248P::xmpE(F354E), KCCM12248P::xmpE(F354M), KCCM12248P::xmpE(F354W), They were named KCCM12248P::xmpE(F354T), KCCM12248P::xmpE(F354Q), KCCM12248P::xmpE(F354K), KCCM12248P::xmpE(F354L), and KCCM12248P::xmpE(F354H).
[0457]
[0458] 3-3. Confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutation
[0459] Sixteen strains produced in the above Example 3-2, the KCCM12248P::xmpE(F354S) strain, the KCCM12248P::xmpE(F354Y) strain, and the KCCM12248P::xmpE(F354N) strain produced in the above Example 2-2, and the KCCM12248P strain as a control strain were cultured using the fermentation activity evaluation method of the above Example 1-3. After the culture was completed, the production amount of XMP was measured using HPLC, and the results are shown in Table 6 below.
[0460]
[0461] Strain name XMP Concentration (g / L) 1 KCCM12248P 13.52 KCCM12248P::xmpE(F354S) 16.13 KCCM12248P::xmpE(F354Y) 15.74 KCCM12248P::xmpE(F354N) 16.65 KCCM12248P::xmpE(F354L) 14.4
[0462]
[0463] As shown in Table 6 above, it was confirmed that the Corynebacterium stationaris strain, in which a mutation was introduced in which the 354th amino acid from the N-terminus of the MFS transporter was substituted with serine, tyrosine, asparagine, or leucine, showed an increase in XMP production ability of 6% to 22% or more compared to the parent strain KCCM12248P.
[0464]
[0465] Example 4: Vector for introducing mutations at position I259 of the MFS transporter and confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutations
[0466]
[0467] 4-1. Vector creation for introducing MFS transporter mutations
[0468] In the above Example 2-3, it was confirmed that XMP production ability could be increased when the 259th amino acid from the N-terminus of the MFS transporter was mutated, and thus, site-selective mutagenesis was performed using the pDCM2-xmpE (I259T) vector produced in the above Example 2-1 as a template to produce a vector in which the 259th amino acid was replaced with another amino acid.
[0469] Specifically, a primer pair of SEQ ID NO: 177 and SEQ ID NO: 178 for introducing the I259F mutation into the gene encoding the MFS transporter, a primer pair of SEQ ID NO: 179 and SEQ ID NO: 180 for introducing the I259Y mutation, a primer pair of SEQ ID NO: 181 and SEQ ID NO: 182 for introducing the I259C mutation, a primer pair of SEQ ID NO: 183 and SEQ ID NO: 184 for introducing the I259L mutation, a primer pair of SEQ ID NO: 185 and SEQ ID NO: 186 for introducing the I259H mutation, a primer pair of SEQ ID NO: 187 and SEQ ID NO: 188 for introducing the I259V mutation, a primer pair of SEQ ID NO: 189 and SEQ ID NO: 190 for introducing the I259D mutation, a primer pair of SEQ ID NO: 191 and SEQ ID NO: 192 for introducing the I259G mutation, and a primer pair of SEQ ID NO: 193 for introducing the I259P mutation. Site-directed PCR was performed using the primer pairs of SEQ ID NOs: 193 and 194, the primer pairs of SEQ ID NOs: 195 and 196 for introducing the I259A mutation, the primer pairs of SEQ ID NOs: 197 and 198 for introducing the I259E mutation, the primer pairs of SEQ ID NOs: 199 and 200 for introducing the I259M mutation, the primer pairs of SEQ ID NOs: 201 and 202 for introducing the I259W mutation, the primer pairs of SEQ ID NOs: 203 and 204 for introducing the I259Q mutation, the primer pairs of SEQ ID NOs: 205 and 206 for introducing the I259K mutation, the primer pairs of SEQ ID NOs: 207 and 208 for introducing the I259R mutation, and the primer pairs of SEQ ID NOs: 209 and 210 for introducing the I259N mutation.
[0470] The primer sequences used here are as shown in Table 7 below.
[0471]
[0472]
[0473]
[0474] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, polymerization at 72°C for 10 minutes (24 cycles), and then polymerization at 72°C for 5 minutes. The PCR product amplified above was treated with DpnI restriction enzyme to remove the pDCM2-xmpE (I259T) vector used as a template, and then transformed into E. coli DH5a to obtain a vector in which the 259th amino acid of the MFS transporter was modified with the desired amino acid. The 17 vectors obtained above were each pDCM2-xmpE(I259F), pDCM2-xmpE(I259Y), pDCM2-xmpE(I259C), pDCM2-xmpE(I259L), pDCM2-xmpE(I259H), pDCM2-xmpE(I259V), pDCM2-xmpE(I259D), pDCM2-xmpE(I259G), pDCM2-xmpE(I259P), pDCM2-xmpE(I259A), pDCM2-xmpE(I259E), pDCM2-xmpE(I259M), pDCM2-xmpE(I259W), pDCM2-xmpE(I259Q), pDCM2-xmpE(I259K), They were named pDCM2-xmpE(I259R) and pDCM2-xmpE(I259N).
[0475]
[0476] 4-2. Production of Corynebacterium stationaris with MFS transporter mutations
[0477] Each of the 17 vectors manufactured in Example 4-1 was transformed into the Corynebacterium stationarynis KCCM12248P strain by electroporation, thereby obtaining strains in which each vector was inserted into the chromosome by recombination of homologous sequences. The strains were selected on a medium containing 25 mg / L kanamycin. The selected primary strains were subjected to a second round of crossing, and a strain in which the 259th amino acid of the MFS transporter was modified to the desired amino acid was selected. The genetic manipulation was confirmed through PCR using the primer pairs of SEQ ID NOs: 141 and 142 and base sequence analysis using the primer pairs of SEQ ID NOs: 143 and 144.
[0478] The 17 strains obtained above were KCCM12248P::xmpE(I259F), KCCM12248P::xmpE(I259Y), KCCM12248P::xmpE(I259C), KCCM12248P::xmpE(I259L), KCCM12248P::xmpE(I259H), KCCM12248P::xmpE(I259V), KCCM12248P::xmpE(I259D), KCCM12248P::xmpE(I259G), KCCM12248P::xmpE(I259P), KCCM12248P::xmpE(I259A), KCCM12248P::xmpE(I259E), They were named KCCM12248P::xmpE(I259M), KCCM12248P::xmpE(I259W), KCCM12248P::xmpE(I259Q), KCCM12248P::xmpE(I259K), KCCM12248P::xmpE(I259R), and KCCM12248P::xmpE(I259N).
[0479]
[0480] 4-3. Confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutation
[0481] The strain produced in the above Example 4-2, the KCCM12248P::xmpE(I259S) strain and the KCCM12248P::xmpE(I259T) strain produced in the above Example 2-2, and the KCCM12248P strain as a control strain were cultured using the fermentation activity evaluation method of the above Example 1-3. After the culture was completed, the production amount of XMP was measured using HPLC, and the results are shown in Table 8 below.
[0482]
[0483] Strain name XMP concentration (g / L) 1KCCM12248P 13.32KCCM12248P::xmpE(I259S) 15.23KCCM12248P::xmpE(I259T) 15.54KCCM12248P::xmpE(I259F) 13.65KCCM12248P::xmpE(I259P) 13.46KCCM12248P::xmpE(I259M) 14.27KCCM12248P::xmpE(I259Q) 13.58KCCM12248P::xmpE(I259N) 13.4
[0484]
[0485] As shown in Table 8 above, it was confirmed that the Corynebacterium stationaris strain, in which a mutation was introduced in which the 259th amino acid from the N-terminus of the MFS transporter was substituted with serine, threonine, phenylalanine, proline, methionine, glutamine, or asparagine, showed an increase in XMP production ability of 0.7% to 16% or more compared to the parent strain KCCM12248P.
[0486]
[0487] Example 5: Vector for introducing mutations at position V310 of the MFS transporter and confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutations
[0488]
[0489] 5-1. Vector creation for introducing MFS transporter mutations
[0490] In the above Example 2-3, it was confirmed that XMP production ability could be increased when the 310th amino acid from the N-terminus of the MFS transporter was mutated, and thus, site-selective mutagenesis was performed using the pDCM2-xmpE (V310A) vector produced in the above Example 2-1 as a template to produce a vector in which the 310th amino acid was replaced with another amino acid.
[0491] Specifically, a primer pair of SEQ ID NO: 211 and SEQ ID NO: 212 for introducing a V310F mutation into a gene encoding an MFS transporter, a primer pair of SEQ ID NO: 213 and SEQ ID NO: 214 for introducing a V310C mutation, a primer pair of SEQ ID NO: 215 and SEQ ID NO: 216 for introducing a V310L mutation, a primer pair of SEQ ID NO: 217 and SEQ ID NO: 218 for introducing a V310H mutation, a primer pair of SEQ ID NO: 219 and SEQ ID NO: 220 for introducing a V310R mutation, a primer pair of SEQ ID NO: 221 and SEQ ID NO: 222 for introducing a V310I mutation, a primer pair of SEQ ID NO: 223 and SEQ ID NO: 224 for introducing a V310N mutation, a primer pair of SEQ ID NO: 225 and SEQ ID NO: 226 for introducing a V310D mutation, and a primer pair of SEQ ID NO: 226 for introducing a V310G mutation. A primer pair of SEQ ID NO: 227 and SEQ ID NO: 228, a primer pair of SEQ ID NO: 229 and SEQ ID NO: 230 for introducing the V310P mutation, a primer pair of SEQ ID NO: 231 and SEQ ID NO: 232 for introducing the V310E mutation, a primer pair of SEQ ID NO: 233 and SEQ ID NO: 234 for introducing the V310M mutation, a primer pair of SEQ ID NO: 235 and SEQ ID NO: 236 for introducing the V310W mutation, a primer pair of SEQ ID NO: 237 and SEQ ID NO: 238 for introducing the V310S mutation, a primer pair of SEQ ID NO: 239 and SEQ ID NO: 240 for introducing the V310T mutation, a primer pair of SEQ ID NO: 241 and SEQ ID NO: 242 for introducing the V310Q mutation, a primer pair of SEQ ID NO: 243 and SEQ ID NO: 244 for introducing the V310K mutation, and a primer pair of SEQ ID NO: 244 for introducing the V310Y mutation. Site-directed PCR was performed using primer pairs of sequence numbers 245 and 246, respectively.
[0492] The primer sequences used here are as shown in Table 9 below.
[0493]
[0494]
[0495]
[0496] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, followed by 24 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 10 minutes, followed by polymerization at 72°C for 5 minutes. The PCR product amplified above was treated with DpnI restriction enzyme to remove the pDCM2-xmpE (V310) vector used as a template, and then transformed into E. coli DH5a to obtain a vector in which the 310th amino acid of the MFS transporter was modified with the desired amino acid. The 18 vectors obtained above were each pDCM2-xmpE(V310F), pDCM2-xmpE(V310C), pDCM2-xmpE(V310L), pDCM2-xmpE(V310H), pDCM2-xmpE(V310R), pDCM2-xmpE(V310I), pDCM2-xmpE(V310N), pDCM2-xmpE(V310D), pDCM2-xmpE(V310G), pDCM2-xmpE(V310P), pDCM2-xmpE(V310E), pDCM2-xmpE(V310M), pDCM2-xmpE(V310W), pDCM2-xmpE(V310S), pDCM2-xmpE(V310T), They were named pDCM2-xmpE(V310Q), pDCM2-xmpE(V310K), and pDCM2-xmpE(V310Y).
[0497]
[0498] 5-2. Production of Corynebacterium stationaris with MFS transporter mutations
[0499] Each of the 18 vectors manufactured in Example 5-1 was transformed into the Corynebacterium stationarynis KCCM12248P strain by electroporation, thereby obtaining strains in which each vector was inserted into the chromosome by recombination of homologous sequences. The strains were selected on a medium containing 25 mg / L of kanamycin. The selected primary strains were subjected to a second round of crossing, and a strain in which the 310th amino acid of the MFS transporter was modified to the desired amino acid was selected. The genetic manipulation was confirmed through PCR using the primer pairs of SEQ ID NOs: 141 and 142 and base sequence analysis using the primer pairs of SEQ ID NOs: 143 and 144.
[0500] The 18 strains obtained above were respectively KCCM12248P::xmpE(V310F), KCCM12248P::xmpE(V310C), KCCM12248P::xmpE(V310L), KCCM12248P::xmpE(V310H), KCCM12248P::xmpE(V310R), KCCM12248P::xmpE(V310I), KCCM12248P::xmpE(V310N), KCCM12248P::xmpE(V310D), KCCM12248P::xmpE(V310G), KCCM12248P::xmpE(V310P), KCCM12248P::xmpE(V310E), They were named KCCM12248P::xmpE(V310M), KCCM12248P::xmpE(V310W), KCCM12248P::xmpE(V310S), KCCM12248P::xmpE(V310T), KCCM12248P::xmpE(V310Q), KCCM12248P::xmpE(V310K), and KCCM12248P::xmpE(V310Y).
[0501]
[0502] 5-3. Confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutation
[0503] Eighteen strains produced in the above Example 5-2, the KCCM12248P::xmpE (V310A) strain produced in the above Example 2-2, and the KCCM12248P strain as a control strain were cultured using the fermentation activity evaluation method of the above Example 1-3. After the culture was completed, the production amount of XMP was measured using HPLC, and the results are shown in Table 10 below.
[0504]
[0505] Strain name XMP Concentration (g / L) 1 KCCM12248P 13.62 KCCM12248P::xmpE (V310A) 14.03 KCCM12248P::xmpE (V310F) 14.24 KCCM12248P::xmpE (V310C) 14.55 KCCM12248P::xmpE (V310I) 14.16 KCC M12248P::xmpE(V310G)14.97KCCM12248P::xmpE(V310M)15.08KCCM12248P::xmp E(V310W)13.99KCCM12248P::xmpE(V310S)14.110KCCM12248P::xmpE(V310T)14.4
[0506]
[0507] As shown in Table 10 above, it was confirmed that the Corynebacterium stationaris strain, in which a mutation was introduced in which the 310th amino acid from the N-terminus of the MFS transporter was substituted with alanine, phenylalanine, cysteine, isoleucine, glycine, methionine, tryptophan, serine, or threonine, showed an increase in XMP production ability of 2% to 10% or more compared to the parent strain KCCM12248P.
[0508]
[0509] Example 6: Vector for introducing mutations at homologous positions of MFS transporter variants and confirmation of XMP production ability of Corynebacterium stationaris introducing MFS transporter variant mutations
[0510]
[0511] 6-1. Vector construction for introduction of MFS transporter variants
[0512] Plasmids were constructed to introduce the I238T and F354S mutations, which have excellent XMP production ability when introduced into Corynebacterium stationensis, into positions homologous to the MFS transporters derived from Corynebacterium glutamicum ATCC13032 and Corynebacterium glutamicum ATCC13869, respectively.
[0513] The positions in Corynebacterium glutamicum ATCC13032 and Corynebacterium glutamicum ATCC13868 that are homologous to positions I238 and F354 of Corynebacterium stationenis are as shown in Table 11 below.
[0514]
[0515] Strain name: Corynebacterium stationis, Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC13869, homologous position: F354, F347, F332, I238, I231, I216
[0516]
[0517] First, a vector was constructed to delete the gene encoding the endogenous MFS transporter of Corynebacterium stationensis and introduce a gene encoding the MFS transporter derived from Corynebacterium glutamicum ATCC13032 and Corynebacterium glutamicum ATCC13868 into the corresponding position. Specifically, to construct a vector for introducing a gene encoding an MFS transporter derived from Corynebacterium glutamicum ATCC13032, PCR was performed using the genomic DNA of wild-type Corynebacterium stationensis ATCC6872 as a template and the primer pairs of SEQ ID NO: 247 and SEQ ID NO: 248, and the primer pairs of SEQ ID NO: 251 and SEQ ID NO: 252, and to obtain an MFS transporter derived from Corynebacterium glutamicum ATCC13032, PCR was performed using the genomic DNA of Corynebacterium glutamicum ATCC13032 as a template and the primer pairs of SEQ ID NO: 249 and SEQ ID NO: 250.
[0518]
[0519] To construct a vector for introducing a gene encoding an MFS transporter derived from Corynebacterium glutamicum ATCC13869, PCR was performed using the genomic DNA of wild-type Corynebacterium stationensis ATCC6872 as a template and the primer pairs of SEQ ID NO: 247 and SEQ ID NO: 253, and the primer pairs of SEQ ID NO: 256 and SEQ ID NO: 252. To obtain an MFS transporter derived from Corynebacterium glutamicum ATCC13869, PCR was performed using the genomic DNA of Corynebacterium glutamicum ATCC13869 as a template and the primer pairs of SEQ ID NO: 254 and SEQ ID NO: 255.
[0520] The primer sequences used here are as shown in Table 12 below.
[0521]
[0522] 서열번호서열명서열(5'-> 3')247pDC-xmpE-LA-FAGCTCGGTACCCGGGGATCCTCGCATCGGGTAGGATCTGCA248xmpE-LA-(Cgl13032)-RccttcttcagctacggacaTGATTCTCCTTACTGCAGTTA249(xmpE-LA)-Cgl130AACTAG-FTAACTGCA248xmpE-LA-(Cgl13032) TAAGGAGAATCAtgtccgtagctgaagaagg250Cgl13032-(xmpE-RA)-RTCCCTTGGCTCAAATATTTActagctaactaaagcgacag251(Cgl13032)-xmpE-RA-FctgtcgctttagttagctagTAAATATTTGAGCCAGGGG A252pDC-xmpE-RA-RTGCATGCCTGCAGGTCGACTATGAATGCCCACAGGAACAGCA253xmpE-LA-(Cgl13869)-RAGGTTGGCAAACCATCCCATGATTCTCCTTACTGCAGTTA254(xmpE-LA)-Cgl13869-FTAACTGCTA AGGAGAATCATGGGATGGTTTGCCAACCT255Cgl138692-(xmpE-RA)-RTCCCTTGGCTCAAATATTTACTAGCTAACTAAAGCGACAG256(Cgl13869)-xmpE-RA-FCTGTCGCTTTAGTTAGCTAGTAAAATTTGAGCCAAGGGAGGA
[0523]
[0524] 이 때, 중합효소는 Solg TMPfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, polymerization at 72°C for 60 seconds, and then polymerization at 72°C for 5 minutes. The recombinant vector was obtained by cloning the PCR product amplified above and the vector pDCM2 for chromosomal transformation digested with XbaI restriction enzyme using the Gibson assembly method. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar number and then storing at 50°C for 1 hour. The recombinant vectors constructed above were named pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13032) and pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13869) vectors, respectively.
[0525]
[0526] 6-2. Vector construction for introducing MFS transporter variants
[0527] Next, vectors were constructed to introduce the mutations in Table 11 into the MFS transporters derived from Corynebacterium glutamicum ATCC13032 and Corynebacterium glutamicum ATCC13869, respectively.
[0528]
[0529] First, a vector for introducing the I231T or F347S mutation into the MFS transporter derived from Corynebacterium glutamicum ATCC13032 was constructed by site-selective mutagenesis.
[0530] Specifically, site-directed PCR was performed using the pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13032) vector produced in Example 6-1 as a template, the primer pair of SEQ ID NOs: 257 and 258 for introducing the MFS transporter (I231T) mutation, and the primer pair of SEQ ID NOs: 259 and 260 for introducing the MFS transporter (F347S) mutation.
[0531]
[0532] Next, a plasmid was constructed to introduce the I216T or F332S mutation into the MFS transporter derived from Corynebacterium glutamicum ATCC13869.
[0533] Specifically, site-directed PCR was performed using the pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13869) vector produced in Example 2 as a template, the primer pair of SEQ ID NOs: 257 and 258 for introducing the MFS transporter (I216T) mutation, and the primer pair of SEQ ID NOs: 259 and 260 for introducing the MFS transporter (F332S) mutation.
[0534] The primer sequences used here are as shown in Table 13 below.
[0535]
[0536] SEQ ID NO Sequence Name Sequence (5'-> 3') 257C. gl 13032 I231T / C. gl 13869 I216Tgcttactctggcgtcaccgcctacatcaacgcattt258C. gl 13032 I231T / C. gl 13869 I216Taaatgcgttgatgtaggcggtgacgccagagtaagc259C. gl 13032 F347S / C. gl 13869 F332Sgtttgtggacttaggttccggctttggacctatt260C. gl 13032 F347S / C. gl 13869 F332Saataggtccaaagccggaacctaagtccacaaac
[0537]
[0538] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification was performed under the following conditions: denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, polymerization at 72°C for 10 minutes, repeated 24 times, and then polymerization at 72°C for 5 minutes. The PCR product amplified above was treated with DpnI restriction enzyme to remove the pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13032) or pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13869) vector used as a template, and then transformed into E. coli DH5a strain to obtain a plasmid in which a specific amino acid of the MFS transporter was mutated. The recombinant plasmids obtained above were named pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13032, I231T), pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13032, F347S), pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13869, I216T), and pDCM2-△xmpE(C.st)_MFS transporter(C.gl ATCC13869, F332S) vectors, respectively.
[0539]
[0540] 6-3. Production of Corynebacterium stationaris with MFS transporter mutations
[0541] Each of the six vectors constructed in Examples 6-1 and 6-2 was transformed into Corynebacterium stationensis KCCM12248P by electroporation, thereby obtaining strains in which each vector was inserted into the chromosome by recombination of homologous sequences. The strains were selected on a medium containing 25 mg / L of kanamycin. The selected primary strains were crossed a second time, and strains in which a gene encoding an MFS transporter mutant was introduced were selected. The genetic manipulation was confirmed through PCR and base sequence analysis using primer pairs of SEQ ID NOs: 143 and 144.
[0542] Six strains into which the gene encoding the MFS transporter variant obtained above was introduced were named KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13032), KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13869), KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13032, I231T), KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13032, F347S), KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13869, I216T), It was named KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13869, F332S).
[0543]
[0544] 6-4. Confirmation of XMP production ability of Corynebacterium stationaris with MFS transporter mutation
[0545] Six strains into which a gene encoding the MFS transporter mutant variant produced in Example 6-3 was introduced were cultured using the fermentation activity evaluation method of Example 1-3. After completion of cultivation, the production amount of XMP was measured using HPLC, and the results are shown in Table 14 below.
[0546]
[0547] Strain name I231T)6.5KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13032, F347S)6.3KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13869)11.4KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13869, I216T)12.5KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13869, F332S)12.8
[0548]
[0549] As shown in Table 14 above, it was confirmed that the mutant introduced with a mutation into the MFS transporter derived from Corynebacterium glutamicum ATCC13032 had an XMP production ability increased by 14% to 18% or more compared to the wild-type protein of the MFS transporter derived from Corynebacterium glutamicum ATCC13032. In addition, it was confirmed that the mutant introduced with a mutation into the MFS transporter derived from Corynebacterium glutamicum ATCC13869 had an XMP production ability increased by 9% to 12% or more compared to the wild-type protein of the MFS transporter derived from Corynebacterium glutamicum ATCC13869.
[0550]
[0551] Example 7: Confirmation of GMP (5'-guanosine monophosphate) production ability of Corynebacterium stationensis introduced with MFS transporter mutant.
[0552] GMP production was confirmed using the XMP culture solution of the KCCM12248P::xmpE(I238T), KCCM12248P::xmpE(I259S), KCCM12248P::xmpE(V310A), KCCM12248P::xmpE(F354S), KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13032), and KCCM12248P::△xmpE(C.st)_MFS transporter(C.gl ATCC13869) strains, whose XMP production ability was confirmed in Examples 2-3 and 6, as follows (Republic of Korea Patent Publication No. 10-2011-0105662).
[0553] Specifically, the strain was cultured using the method of Example 4, and after the culture was completed, the amount of XMP produced was measured using HPLC. In order to convert the produced XMP into GMP, the following conversion reaction additives and E. coli-derived XMP aminase were added to the XMP culture solution, and the conversion reaction was performed at 40°C for 2.5 hours. After the reaction was completed, the amount of GMP produced was measured using HPLC, and the results are shown in Table 15 below.
[0554] The composition of the above conversion reaction additive is as follows.
[0555]
[0556] <Conversion reaction additive>
[0557] Phytic acid 1.8g / L, magnesium sulfate 4.8g / L, nymeen 3㎖ / L, xylene 2%, adenine 100mg / L, sodium hydrogen phosphate (Na2HPO4) 7.7g / L, glucose 46g / L (based on 1L of distilled water)
[0558]
[0559] Strain nameConcentration (g / L)Conversion rate (%)XMPGMP(GMP production / XMP consumption)KCCM12248P::xmpE(I238T)15.111.374.8KCCM12248P::xmpE(I259S)15.011.274.7KCCM12248P::xmpE(V310A)13.59.973.3KCCM12248P::xmpE(F354S)15.911.874.2KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13032)5.23.771.2KCCM12248P::ΔxmpE(C.st)_MFS transporter(C.gl ATCC13869)11.18.072.1
[0560]
[0561] As shown in Table 15 above, it was confirmed that GMP was produced at a level of about 71 to 75% of the amount of XMP produced through conversion reaction from XMP produced by the strains KCCM12248P::xmpE(I238T), KCCM12248P::xmpE(I259S), KCCM12248P::xmpE(V310A), KCCM12248P::xmpE(F354S), KCCM12248P::△xmpE(C.st)_MFS Transporter(C.gl ATCC13032), and KCCM12248P::△xmpE(C.st)_MFS Transporter(C.gl ATCC13869).
[0562] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
Claims
1. An MFS transporter variant, wherein any one amino acid selected from the group consisting of amino acids corresponding to positions 185, 238, 259, 283, 310, 354, 378, 383, and 403 of SEQ ID NO: 1 in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity with SEQ ID NO: 1 is substituted with another amino acid.
2. In the first paragraph, a variant wherein the substitution with another amino acid is one selected from the following: (1) The amino acid corresponding to position 259 is replaced with an amino acid selected from serine, threonine, phenylalanine, proline, methionine, glutamine, and asparagine; (2) The amino acid corresponding to position 310 is replaced with an amino acid selected from alanine, phenylalanine, cysteine, isoleucine, glycine, methionine, tryptophan, serine, and threonine; (3) The amino acid corresponding to position 354 is replaced with an amino acid selected from serine, tyrosine, asparagine, and leucine; (4) The amino acid corresponding to position 185 is replaced with glutamine; (5) The amino acid corresponding to position 238 is replaced with threonine; (6) The amino acid corresponding to position 283 is substituted with glycine; (7) The amino acid corresponding to position 378 is replaced with alanine; (8) The amino acid corresponding to position 383 is substituted with leucine; and (9) The amino acid corresponding to position 403 is replaced with alanine.
3. In the first paragraph, the variant is a variant consisting of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 51, 55, 57, 59, 75, 81, 85, 91, 93, 95, 97, 105, 111, 117, 119, 121, 123, and 131.
4. In the first paragraph, the mutant is an MFS transporter mutant in which an amino acid corresponding to any one position selected from the group consisting of positions 231 and 347 in the amino acid sequence of SEQ ID NO: 3 is substituted with another amino acid.
5. In the fourth paragraph, the variant comprises a substitution selected from among a substitution of the amino acid corresponding to position 231 in the amino acid sequence of SEQ ID NO: 3 with threonine and a substitution of the amino acid corresponding to position 347 with serine.
6. In the fourth paragraph, the variant is a variant consisting of an amino acid sequence of SEQ ID NO: 133 or 135.
7. An MFS transporter variant in which an amino acid corresponding to any one position selected from the group consisting of positions 216 and 332 in the amino acid sequence of SEQ ID NO: 5 is replaced with another amino acid in the first paragraph.
8. In the 7th paragraph, the variant comprises a substitution selected from among a substitution of the amino acid corresponding to position 216 in the amino acid sequence of SEQ ID NO: 5 with threonine and a substitution of the amino acid corresponding to position 332 with serine.
9. In the 7th paragraph, the variant is a variant consisting of an amino acid sequence of SEQ ID NO: 137 or 139.
10. A polynucleotide encoding an MFS transporter variant of any one of claims 1 to 9.
11. A microorganism of the genus Corynebacterium, comprising at least one selected from the group consisting of an MFS transporter variant of any one of claims 1 to 9; a polynucleotide encoding the same; and a vector comprising the same.
12. A microorganism according to claim 11, wherein the microorganism has the ability to produce purine nucleotides.
13. In the 12th paragraph, the microorganism has an increased purine nucleotide production ability compared to a wild-type Corynebacterium microorganism.
14. A microorganism according to claim 12, wherein the purine nucleotide is at least one selected from XMP and GMP.
15. A microorganism according to claim 11, wherein the microorganism is Corynebacterium stationaryus.
16. A method for producing purine nucleotides, comprising the step of culturing a microorganism of the genus Corynebacterium in a medium, the microorganism comprising at least one selected from the group consisting of an MFS transporter variant of any one of claims 1 to 9; a polynucleotide encoding the same; and a vector comprising the same.
17. A method according to claim 16, further comprising a step of recovering purine nucleotides from a culture medium or a cultured microorganism.
18. A method according to claim 16, wherein the purine nucleotide is at least one selected from XMP and GMP.
19. Use of a strain of the genus Corynebacterium, wherein at least one of the MFS transporter variants of any one of claims 1 to 9; a polynucleotide encoding the same; and a vector comprising the same have been introduced, for producing purine nucleotides.
Citation Information
Patent Citations
Novel promoter and purine nucleotide production method using same
EP3722430A1
A Microorganism producing 5'-Xanthylic acid
KR100542568B1
Novel promoter nucleic acid derived from corynebacterium genus bacteria, expression cassette comprising the promoter and vector comprising the cassette, host cell comprising the vector and method for expressing a gene using the cell
KR100620092B1
Novel promoter and uses thereof
KR101632642B1
A novel promoter and use thereof
KR101783170B1
